<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003871" GROUP_ID="SKIN" ID="431801102612011299" MERGED_FROM="" MODIFIED="2008-05-13 16:26:37 +0200" MODIFIED_BY="Diane Horsley" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;received from Jane 21 aug 02 - for CLIB&lt;br&gt;28 August copy editing UF&lt;/p&gt;&lt;p&gt;10dec02 - added sentence to search strat:&lt;br&gt;5. ADVERSE EFFECTS &lt;br&gt; A search for side effects studies will be carried out and contact will be made with various adverse reaction reporting bodies.&lt;/p&gt;&lt;p&gt;21 feb03 - updated ASSESSMENT OF METHODOLOGICAL QUALITY section after discussion with PM and SH&lt;/p&gt;&lt;p&gt;26-02-03, 03-03-03 (EP) This version has been edited as a model that conforms with the Cochrane Style Guide, Version 1.0.1 (7 Jan 2003). Have changed spacing, capitalisation, number format, etc, as well as order of references listed in text (ie in date, then alphabetical order).&lt;/p&gt;&lt;p&gt;29july03 (EP) This version has been updated with changes to the Search strategy from FD, and use of italics for scientific species names.&lt;br&gt;1stFeb05 (KJ) Saved as a review file and added text in red to help with conversion to review. Reformatted subheadings in line with Style guide.&lt;/p&gt;&lt;p&gt;FBH has made some changes 17th June 06&lt;/p&gt;&lt;p&gt;26th July 06 (AB/FBH) Final version 1&lt;br&gt;Exported to Fiona - back Sep&lt;br&gt;Exported back to Andy 3.11.06&lt;/p&gt;&lt;p&gt;13Dec06 -I have pasted in the search strats and made comments to Andrew in red italics Finola&lt;/p&gt;&lt;p&gt;Made all relevant changes highlighted in red. Now all red is black. 15th Jan 2007&lt;br&gt;18th May 2007 - made changes to reviewers&lt;/p&gt;&lt;p&gt;Review received by editorial base 24 July 2007&lt;/p&gt;&lt;p&gt;14 Nov 07 DAH basic copy edit to prepare for peer review&lt;/p&gt;&lt;p&gt;11Dec07 I have made amends to the search section in red and made comments to Andrew in red italics. Finola&lt;br&gt;Old title: Interventions to reduce Staphylococcus aureus in the management of atopic eczema&lt;/p&gt;&lt;p&gt;14 Mar 08 DAH recieved from authors post pr , checked, and saved into Archie and shared drive&lt;/p&gt;" NOTES_MODIFIED="2008-05-13 15:25:08 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" REVIEW_NO="#43" REVMAN_SUB_VERSION="5.0.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2008-05-13 16:26:37 +0200" MODIFIED_BY="Diane Horsley">
<TITLE>Interventions to reduce Staphylococcus aureus in the management of atopic eczema</TITLE>
<CONTACT MODIFIED="2008-05-13 16:26:37 +0200" MODIFIED_BY="Diane Horsley"><PERSON ID="FC9DD62C82E26AA20093068ADCA9B6B3" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Birnie</LAST_NAME><POSITION>SpR</POSITION><EMAIL_1>birnie@doctors.net.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dermatology</DEPARTMENT><ORGANISATION>Nottingham University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Derby Road</ADDRESS_1><ADDRESS_2>Queen's Medical Centre Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-05-13 16:26:37 +0200" MODIFIED_BY="Diane Horsley"><PERSON ID="FC9DD62C82E26AA20093068ADCA9B6B3" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Birnie</LAST_NAME><POSITION>SpR</POSITION><EMAIL_1>birnie@doctors.net.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dermatology</DEPARTMENT><ORGANISATION>Nottingham University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Derby Road</ADDRESS_1><ADDRESS_2>Queen's Medical Centre Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16321" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Bath-Hextall</LAST_NAME><POSITION>Associate Professor, </POSITION><EMAIL_1>fiona.bath-hextall@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07816925547</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Nursing, Faculty of Medicine and Health Science</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Room D83, Medical school</ADDRESS_1><ADDRESS_2>Queens medical centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8230884</PHONE_1></ADDRESS></PERSON><PERSON ID="16392" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane Catherine</FIRST_NAME><LAST_NAME>Ravenscroft</LAST_NAME><POSITION>Consultant Dermatologist</POSITION><EMAIL_1>jcravenscroft@doctors.net.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dermatology</DEPARTMENT><ORGANISATION>Nottingham University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Derby Road</ADDRESS_1><ADDRESS_2>Queen's Medical Centre Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 924 9924 ext: 4752</PHONE_1><PHONE_2>+44 7931 510836</PHONE_2></ADDRESS></PERSON><PERSON ID="5ABF850A82E26AA20187B796CC44F156" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Hywel</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Williams</LAST_NAME><POSITION>Professor of Dermato-Epidemiology</POSITION><EMAIL_1>hywel.williams@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre of Evidence-Based Dermatology</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Queen's Medical Centre</ADDRESS_1><ADDRESS_2>Derby Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1048</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-03 10:37:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 12/10/02&lt;/p&gt;" NOTES_MODIFIED="2008-04-03 10:37:49 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="3" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="3" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="14" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-13 14:19:25 +0100" MODIFIED_BY="Diane A  Horsley"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Queens Medical Centre NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-13 15:25:08 +0100" MODIFIED_BY="Diane A  Horsley">
<SUMMARY MODIFIED="2008-04-29 14:15:56 +0100" MODIFIED_BY="Diane A  Horsley">
<TITLE MODIFIED="2008-04-29 13:39:42 +0100" MODIFIED_BY="Diane A  Horsley">Interventions to reduce <I>Staphylococcus aureus</I> in the management of atopic eczema</TITLE>
<SUMMARY_BODY MODIFIED="2008-04-29 14:15:56 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Atopic eczema (atopic dermatitis or childhood eczema) is a big problem worldwide. The skin of people with atopic eczema often contains high numbers of a bacterium called <I>Staphylococcus aureus (S. aureus). </I>
</P>
<P>Sometimes <I>S. aureus</I> results in an obvious secondary infection. Even when the eczema does not look infected <I>S. aureus</I> may still play a part in promoting skin inflammation. As a result, lots of eczema treatments have been developed to reduce <I>S. aureus</I>, including antibiotics taken by mouth, washing with antibacterial soaps or antibiotics combined with other eczema treatments. We undertook a systematic review on this topic as it is not clear which treatments offer any clinical benefit and because there is some concern that their widespread use may promote bacterial resistance.</P>
<P>Our review included 21 randomised controlled trials involving 1018 participants covering a range of anti-staphylococcal treatments: oral antibiotics (3 trials), antibacterial soaps (1 trial), topical steroids combined with antibacterials (10 trials), antibacterial bath additives (2 trials), topical antiseptic/antibiotics creams (4 trials) and silver impregnated textiles (1 trial). Generally, the quality of the reported studies was poor, and many were too small to identify important differences even if they existed. None of the trials showed any clear benefit in terms of short-term eczema control for any of the interventions tested, although several interventions were associated with decreased numbers of <I>S. aureus</I> on the skin. There was no clear evidence that widely used topical steroid/antibiotic combinations were any better than the topical steroids used alone. Adverse effects like irritation were especially poorly reported and only one study reported on the emergence of resistant bacterial strains in the group treated with oral antibiotics. Only one small inconclusive study evaluated people with clinically infected eczema.</P>
<P>Care should be taken in interpreting the above studies as failure to show benefit in a series of small, poorly reported studies does not mean that the anti-staphylococcal interventions could not be helpful in eczema. It is clinical common sense to treat overtly infected eczema with oral antibiotics, and that practice should continue until good evidence suggests otherwise. However, given that none of the other studies showed clear clinical benefit for anti-staphylococcal interventions in non-infected eczema, their continued use should be questioned in such situations. More studies should be done to look at the long-term possible benefits and harms of such interventions in preventing flares of atopic eczema.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-12 14:44:51 +0100" MODIFIED_BY="Finola M Delamere">
<ABS_BACKGROUND MODIFIED="2008-04-29 13:37:11 +0100" MODIFIED_BY="Diane A  Horsley">
<P>
<I>Staphylococcus aureus</I> can cause secondary infection in atopic eczema, and it may promote inflammation in eczema that does not look infected. Many antimicrobial products exist for eczema, but it is unclear if they work or if they promote bacterial resistance.
<BR/>

</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-04-29 13:37:24 +0100" MODIFIED_BY="Diane A  Horsley">
<P>To assess the effects of interventions to reduce <I>Staphylococcus aureus</I> for treating infected or uninfected atopic eczema.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-04-29 13:38:26 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We searched the Cochrane Skin Group Specialised Register (March 2008), the Cochrane Central Register of Controlled Trials (<I>Cochrane Library </I>Issue 1, 2008), MEDLINE (OVID) (from 2002 to March 2008), EMBASE (OVID) (from 2002 to March 2008), Ongoing trials registers (March 2008). References from trials and reviews were searched, pharmaceutical companies were contacted for unpublished trials. There were no language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) of people with atopic eczema who have been treated with a product intended to reduce <I>S. aureus</I> on the skin.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-12 14:44:51 +0100" MODIFIED_BY="Finola M Delamere">
<P>Two people independently performed the study selection, data abstraction and quality assessment.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-04-29 13:38:52 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We included 21 studies (1018 participants) covering 7 treatment categories. Most studies were poorly reported and study differences limited pooling of results. Adverse effects were especially poorly reported, and only one study reported the emergence of resistant bacterial strains following oral antibiotics. Oral antibiotics were not associated with benefit in non-infected (2 trials, 66 participants) or infected eczema (1 trial, 33 participants). We did not find any benefit for antibacterial soaps (1 trial, 50 participants), or antibacterial bath additives (2 trials, 41 participants), or topical antibiotics/antiseptics (4 studies, 95 participants). Adding antibiotics to topical corticosteroids reduced numbers of <I>Staphylococcus aureus</I> in 4 trials (302 participants), but there was no evidence of any clinical benefit in 9 trials involving 677 participants: betamethasone plus neomycin vs clobetasol (MD 1.2; 95% CI 0.25, 2.15), prednicarbate plus antimicrobial vs prednicarbate (RR 0.64; 95% CI 0.25, 1.68), or betamethasone valerate plus gentamicin vs betamethasone (RR 0.31; 95% CI 0.07, 1.35). One trial (30 participants) showed no significant improvement in eczema for those using silver textiles (RR 2.67; 95% CI 0.98, 7.22), despite using 10 times the amount of topical steroids.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-04-29 13:39:09 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We failed to find clear evidence of benefit for antimicrobial interventions for people with atopic eczema, despite their widespread use. This does not necessarily mean they do not work because the studies were small and poorly reported. Further large studies with long-term outcomes and clearly defined participants are urgently required.
<BR/>

</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-13 15:25:08 +0100" MODIFIED_BY="Diane A  Horsley">
<BACKGROUND MODIFIED="2008-03-17 15:35:40 +0000" MODIFIED_BY="Finola M Delamere">
<CONDITION MODIFIED="2008-05-12 14:50:20 +0100" MODIFIED_BY="Finola M Delamere">
<P>Atopic eczema (syn: atopic dermatitis) is a chronic, relapsing, intensely itchy, inflammatory skin disease, which involves the skin creases such as the folds of the elbows or behind the knees (<LINK REF="REF-Williams-1994" TYPE="REFERENCE">Williams 1994</LINK>). Symptoms usually appear below the age of 2 years and around 60% of cases will be clear by early adolescence, although some will relapse or continue into adult life. The prevalence of atopic eczema varies considerably from one country to another, and also within countries (<LINK REF="REF-Williams-1999" TYPE="REFERENCE">Williams 1999</LINK>). In the UK there has been a steady increase in prevalence, and the condition now affects around 15% of schoolchildren (<LINK REF="REF-Kay-1994" TYPE="REFERENCE">Kay 1994</LINK>; <LINK REF="REF-Neame-1995" TYPE="REFERENCE">Neame 1995</LINK>; <LINK REF="REF-Emerson-1997" TYPE="REFERENCE">Emerson 1997</LINK>) and 1 to 2% of adults.</P>
<P>The cause of atopic eczema is unknown but evidence suggests a role for both genetic and environmental factors in determining both the occurrence and the severity of disease (<LINK REF="REF-Williams-1992" TYPE="REFERENCE">Williams 1992</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="3">Staphylococcus aureus and atopic eczema</HEADING>
<P>An association between <I>S.</I> <I>aureus</I> and atopic eczema has been recognized for many years. It has been demonstrated that <I>S. aureus</I> can be isolated from 90% of atopic eczema skin lesions (<LINK REF="REF-Leyden-1974" TYPE="REFERENCE">Leyden 1974</LINK>) and the density of <I>S.aureus</I> tends to increase with the clinical severity (<LINK REF="REF-Williams-1990" TYPE="REFERENCE">Williams 1990</LINK>). In contrast, <I>S. aureus</I> is rarely found on healthy skin (&lt;5%), and it is less common to have severe colonisation or infection in other skin diseases, so atopic eczema does appear to be a special case. However, whilst this association is well recognized, the role of <I>S. aureus</I> in causing atopic eczema or making it worse, as opposed to simply colonising the skin, is still under debate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinically infected atopic eczema</HEADING>
<P>At one end of the spectrum there is undoubtedly a clinical condition of 'infected atopic eczema' manifest by oozing, crusting and presence of pus spots overlying the areas of pre-existing eczema. This corresponds with heavy growth of bacteria in the laboratory on swabs taken from the affected areas, usually of <I>S. aureus</I>, but there are also reports of beta haemolytic streptococci being isolated either alone or in combination with <I>S. aureus</I>. In this situation the overt infection responds to antibiotic treatment, although the atopic eczema itself may not. Clinical infection is a major problem for some atopic eczema sufferers (<LINK REF="REF-David-1986" TYPE="REFERENCE">David 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">S. aureus and non-clinically infected atopic eczema: coloniser or pathogen?</HEADING>
<P>In atopic eczema that is not overtly clinically infected, the role of <I>S. aureus</I> is much less clear. It may be that <I>S. aureus</I> simply colonises the skin, taking advantage of a favourable environment for growth. This is supported by the fact that treatment of the underlying atopic eczema with topical steroid alone drastically reduces the number of colonies of <I>S. aureus</I> (<LINK REF="REF-Stalder-1994" TYPE="REFERENCE">Stalder 1994</LINK>).</P>
<P>However, several possible mechanisms for a pathogenic role have also been suggested. There may be a direct chemical irritation or a non-specific reaction of the protein A component of the bacterium with immune cells (<LINK REF="REF-White-1985" TYPE="REFERENCE">White 1985</LINK>). Great interest has been shown in possible mechanisms involving superantigens (<LINK REF="REF-McFadden-1993" TYPE="REFERENCE">McFadden 1993</LINK>). The superantigen theory proposes that <I>S. aureus</I> exacerbates or maintains skin inflammation in atopic eczema by secreting a group of toxins, which are capable of stimulating large populations of T-lymphocytes distant from the eczematous site, giving rise to widespread activation of existing lesions. Several lines of investigation support a role for superantigens in atopic eczema (<LINK REF="REF-Leung-2000" TYPE="REFERENCE">Leung 2000</LINK>). First, it has been shown that such toxins can be produced by <I>S. aureus</I> isolated from atopic eczema patients, and that in these patients a T-lymphocyte expansion consistent with superantigen stimulation has occurred. Second, most atopic eczema sufferers make specific IgE antibodies directed against superantigen toxins found on their skin. Third, a correlation has been found between the presence of these antibodies and the severity of the eczema. Finally, the application of one specific superantigen to the skin has been shown to induce skin changes of erythema and thickening of the skin (<LINK REF="REF-Strange-1996" TYPE="REFERENCE">Strange 1996</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-05-12 14:55:51 +0100" MODIFIED_BY="Finola M Delamere">
<P>As a consequence of such findings, it is not surprising that a number of products with anti-staphylococcal properties have been developed for the treatment of atopic eczema, both clinically infected and uninfected, ranging from antibacterial soaps, impregnated clothing, to additives to bath oils and topical corticosteroids.</P>
<SUBSECTION>
<HEADING LEVEL="3">Possible concern about anti-staphylococcal treatment in atopic eczema</HEADING>
<P>Quite apart from the fundamental question of whether anti-staphylococcal therapies work in atopic eczema, there are special concerns about their routine use in non-clinically infected eczema. For the individual patient, irritant and allergic contact dermatitis can occur from topically applied antiseptics or antibiotic containing preparations. The potential for development of bacterial resistance to antibiotics, which may be needed for systemic treatment of serious infections in the community, is also important. A recent increase in the prevalence of fusidic acid resistant <I>S. aureus</I> has been observed in several areas of the UK (<LINK REF="REF-Reed-1999" TYPE="REFERENCE">Reed 1999</LINK>; <LINK REF="REF-Ravenscroft-2000" TYPE="REFERENCE">Ravenscroft 2000</LINK>; <LINK REF="REF-Simpson_x002d_Dent-2000" TYPE="REFERENCE">Simpson-Dent 2000</LINK>; <LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). In Harrogate, UK fusidic acid resistance has been shown to be associated with intensive local use of oral and topical fusidic acid containing preparations such as those marketed for use in eczema (<LINK REF="REF-Ravenscroft-2000" TYPE="REFERENCE">Ravenscroft 2000</LINK>). Such widespread use may limit the use of fusidic acid combination therapies for the treatment of more serious diseases including staphylococcal bone and joint infections and systemic methicillin-resistant <I>S. aureus</I> (MRSA) infections.</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-04-29 13:48:40 +0100" MODIFIED_BY="Diane A  Horsley">
<P>There is a plausible theoretical rationale for use of anti-staphylococcal agents. Yet existing evidence to support clinical benefit of anti-staphylococcal agents appears to be conflicting. There are concerns regarding adverse event issues, e.g. contact and irritant dermatitis, and promoting wider drug resistance in the community. Despite these concerns, anti-staphylococcal products are widely marketed and used by the clinical community.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of interventions to reduce <I>S. aureus</I> for treating atopic eczema.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials, including cross-over trials and randomised within-patient trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-04-29 13:48:50 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Anyone who has been diagnosed with atopic eczema by a medical practitioner. We regarded diagnostic criteria such as the Hanifin and Rajka definition (<LINK REF="REF-Hanifin-1980" TYPE="REFERENCE">Hanifin 1980</LINK>) or the UK modification (<LINK REF="REF-Williams-1994" TYPE="REFERENCE">Williams 1994</LINK>) as acceptable, as was diagnosis of atopic eczema by a dermatologist using the terms 'atopic eczema' or 'atopic dermatitis'. We only accepted the term 'eczema' when referring to children. Any other terms, such as 'Besnier's Prurigo' or 'Neurodermatitis,' had to have additional descriptive evidence of atopic eczema in the flexures before inclusion. It was noted whether the participants were described as 'clinically infected' or otherwise.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-04-29 13:49:08 +0100" MODIFIED_BY="Diane A  Horsley">
<P>(1) Oral antibiotics known to be active against <I>staphylococcus</I>.<BR/>(2) Antibacterial soaps
<BR/>
(3) Topical steroid plus antibiotic and antifungal agent
<BR/>
(4) Antibacterial bath additives<BR/>(5) Topical antiseptic/antibiotic.<BR/>(6) Combination of antibiotics or antiseptics with other drugs such as corticosteroids.<BR/>(7) Silver impregnated textiles
<BR/>

<BR/>We accepted as comparators no treatment, vehicle only, or another active compound, e.g. topical steroid/antibiotic combination compared against the same topical steroid without the antibiotic.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-03-18 08:42:56 +0000" MODIFIED_BY="Finola M Delamere">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-05-12 16:02:30 +0100" MODIFIED_BY="Finola M Delamere">
<P>(a) Global degree of improvement in symptoms or signs, or both, as rated by the patient or medical practitioner, i.e. percentage with good or excellent improvement. We included both short-term (less than or equal to a month) improvement and long-term (more than one month) benefit.</P>
<P>(b) Improvement in Quality of Life questionnaires.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-04-29 13:49:26 +0100" MODIFIED_BY="Diane A  Horsley">
<P>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.<BR/>(b) Minor patient reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.<BR/>(c) Emergence of antibiotic resistant micro-organisms. Only <I>S. aureus</I> was considered, and we only included studies if swab data before and after the intervention was available. It was planned to take duration of treatment into account when these data were interpreted.</P>
<SUBSECTION>
<HEADING LEVEL="5">Tertiary outcome measures</HEADING>
<P>(a) Global changes in composite rating scales, using a published named scale.<BR/>(b) Changes in the individual signs of atopic eczema as assessed by a physician, e.g. erythema (redness), papules (spots that protrude from the skin surface), vesicles (water blisters), scaling.<BR/>(c) Duration of remission and/or prevention of subsequent flares.<BR/>(d) Change in isolation rate of <I>S. aureus</I>, i.e. isolated or not isolated.<BR/>(e) Change in bacterial counts of <I>S. aureus</I>, i.e. an assessment of quantity of <I>S. aureus</I>.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-03-17 14:52:34 +0000" MODIFIED_BY="Finola M Delamere">
<ELECTRONIC_SEARCHES MODIFIED="2008-04-30 09:54:55 +0100" MODIFIED_BY="Finola M Delamere">
<P>We searched the Cochrane Skin Group's Specialised Register (March 2008) using the following strategy:<BR/>((atopic and dermatitis) or (atopic and eczema) or (neurodermatitis)) AND (staphylococc* or (S. and Aureus) or (Staphylococcus and aureus) or (staphyl* and aureus)) AND (antibiotic* or antiseptic* or anti-infective or dermol or oilatum or emulsiderm or fusidic or fucidic or fucibet or gregoderm or nystaform or quinocort or terra-cortril or timodine or vioform or locoid or betnovate or dermovate or trimovate or synalar or aureocort or triadcortyl or bactroban or flucloxacillin or erythromycin or clinadmycin)</P>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 1,2008) using the strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>:
<BR/>
We searched MEDLINE (OVID) (from 2002 to March 2008) using the strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>

<BR/>
We searched EMBASE (OVID) (from 2002 to March 2008) using the strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>
</P>
<P>The UK Cochrane Centre has an ongoing project to systematically search MEDLINE and EMBASE for reports of trials which are then included in the Cochrane Central Register of Controlled Trials. The searching of MEDLINE and EMBASE was done for this review by the Cochrane Skin Group to cover the years that had not been searched by the UKCC.</P>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing Trials</HEADING>
<P>We searched the following databases for ongoing trials in March 2008 using the terms atopic eczema, atopic dermatitis and <I>Staphylococcus</I> <I>aureus</I>, antimicrobial, antiseptics and anti infective agents.</P>
<UL>
<LI>The metaRegister of Controlled Trials <A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>
</LI>
<LI>The U.S. National Institutes of Health ongoing trials register <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>
</LI>
<LI>The Ongoing Skin Trials register on <A HREF="http://www.nottingham.ac.uk/ongoingskintrials">www.nottingham.ac.uk/ongoingskintrials</A>
</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-05-06 09:10:16 +0100" MODIFIED_BY="Finola M Delamere">
<SUBSECTION>
<HEADING LEVEL="4">References lists</HEADING>
<P>We checked the references of all of the studies that were obtained for assessment for further trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>Where possible we corresponded with trial authors about unpublished and ongoing trials, and by contacting pharmaceutical companies who produce relevant products.</P>
<P>The following drug companies were contacted:<BR/>
</P>
<UL>
<LI>Dermal (Dermol products and Emulsiderm);</LI>
<LI>Stiefel (Oilatum plus);</LI>
<LI>Leo (FucidinH, Fucibet);</LI>
<LI>Unigreg (Gregoderm);</LI>
<LI>Typharm (Nystaform-HC);</LI>
<LI>Quinoderm Ltd (Quinocort);</LI>
<LI>Pfizer (Terra-cortril);</LI>
<LI>R&amp;C (Timodine);</LI>
<LI>Novartis Consumer Health (Vioform-Hydrocortisone);</LI>
<LI>Yamanouchi (Locoid C);</LI>
<LI>GlaxoSmith Kline (Betnovate C, Betnovate N, Dermovate NN, Trimovate);</LI>
<LI>Bioglan (Synalar C, Synalar N);</LI>
<LI>Lederle (Aureocort);</LI>
<LI>Squibb (Triadcortyl);</LI>
<LI>Beecham (Bactroban).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grey literature</HEADING>
<P>Conference proceedings from these meetings were checked for RCTs and where appropriate the trial authors were contacted for further information:</P>
<P>British association of dermatologists annual meeting (from 1980 to 2006);</P>
<P>The American academy of dermatology annual meeting (2006);</P>
<P>The European academy of dermatology and venereology annual meeting (1995, 1998, 1999, 2002, 2003, 2005, 2006).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Language restrictions</HEADING>
<P>There were no language restrictions when we searched for publications. We sought translations of papers in languages other than English by asking dermatological colleagues. Carsten Flohr interpreted papers in German and Yukihiro Ohya performed the data extraction on the paper in Japanese (<LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-03-17 15:55:55 +0000" MODIFIED_BY="Finola M Delamere">
<STUDY_SELECTION MODIFIED="2008-04-29 13:51:11 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two authors checked the titles and abstracts identified from the searches (JR, JP up to December 2003 and then subsequently AB alone). If it was clear that the study did not refer to a randomised controlled trial on atopic eczema, it was excluded. If it was unclear, then the full text of study was obtained for independent assessment by two authors (AB, HCW). The authors decided which trials fit the inclusion criteria. Any disagreement was resolved by discussion between the authors. It was not necessary to refer to a third author. We recorded excluded studies and reasons for exclusion in the excluded studies table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-04-29 14:33:57 +0100" MODIFIED_BY="Diane A  Horsley">
<P>This was performed by two authors (AB, HCW), who independently entered data onto a data extraction form. The authors (AB, HCW) discussed discrepancies between themselves. Missing data were obtained from trial authors where possible. Data were checked and entered into RevMan by AB and FBH. The authors were not blinded to the names of trial authors, journal or institutions.</P>
<P>In the original published protocol outcomes were considered at the end of treatment and this was considered short-term where treatment had been given for two weeks or less and long-term for periods of one month or greater. After discussion (between AB &amp; HCW) however, it was decided that studies of under a month's duration would be considered as reflecting short-term benefit and those of greater than a month as a reasonable minimal time to reflect some disease chronicity. Where the patient rated global assessment was not available, the medical practitioner global rating was used. Both measures were taken into account where both were available. No attempt was made to combine these measures, as they are often not well correlated. In the published protocol skin irritation was to be reported separately as well as within the minor patient adverse events. After discussion (between AB and HCW), it was decided that it was not necessary to report on skin irritation twice and thus it was included in the "minor patient reported adverse events" section only.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-05-06 09:48:29 +0100" MODIFIED_BY="Finola M Delamere">
<P>The quality assessment included an evaluation of the following components for each included study, since there is some evidence that these are associated with biased estimates of treatment effect (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>):<BR/>(a) the method of generation of the randomisation sequence;<BR/>(b) the method of allocation concealment - it was considered 'adequate' if the assignment cannot be foreseen;<BR/>(c) who was blinded/not blinded (participants, clinicians, outcome assessors);<BR/>(d) how many participants were lost to follow-up in each arm (split into post-randomisation exclusions and later losses if possible), and whether participants were analysed in the groups to which they were originally randomised (intention to treat).</P>
<P>In addition, assessment was made of the following:<BR/>(e) degree of certainty that participants have atopic eczema;<BR/>(f) baseline comparison for severity of disease;<BR/>(g) baseline comparison of presence of <I>S. aureus</I>;<BR/>(h) amount of topical steroid used during study period.</P>
<P>The information is recorded in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and a description of the quality of each study is given based on a summary of these components.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-04-29 13:52:04 +0100" MODIFIED_BY="Diane A  Horsley">
<P>For studies with a similar type of intervention (e.g. steroid antibiotic combinations) a meta-analysis was performed to calculate a weighted treatment effect across trials using a random effects model. The results are expressed as risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes, rather than odds ratio as the event rates are common and we do not wish to over estimate the effect, and mean differences (MD and 95% CI) for continuous outcomes. Where it has not been possible to perform a meta-analysis the data have been described qualitatively. Where appropriate we expressed results as number needed to treat (NNT) with 95% confidence interval and the baseline risk to which it applies. </P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-04-29 13:52:42 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We did not perform techniques appropriate for paired designs for cross-over studies due to insufficient data, however where data from the first period were available from a cross over study then they were analysed as if it were a parallel study as suggested in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). For within patient trials, we abstracted from the original paper the paired analysis results and reported these in the review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-05-12 15:03:33 +0100" MODIFIED_BY="Finola M Delamere">
<P>If results for intention-to-treat were given then we used them as such (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Where a per protocol analysis was performed by the study in question or it was clear that the number of participants completing the study were not the same as those randomised then we performed an available case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-04-29 13:56:40 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Heterogeneity was assessed using I<SUP>2</SUP>. Where substantial heterogeneity (I<SUP>2</SUP>&gt;50%) existed between studies for the primary outcome, we explored reasons for heterogeneity, such as differing inclusion criteria.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-04-29 13:56:44 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We performed funnel plots if greater than ten poolable studies were available.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-04-29 13:56:49 +0100" MODIFIED_BY="Diane A  Horsley">
<P>A random effects model was used when conducting a meta-analysis as the studies were deemed to be clinically heterogeneous.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-04-29 13:56:54 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Subgroup analysis was performed where adequate information was given. The planned subgroups were 'clinically infected eczema', 'mixed infection/colonisation with <I>S. aureus</I> and beta haemolytic streptococcus', and 'non infected or unspecified.' Heterogeneity was assessed as above</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-04-29 13:56:59 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We explored reasons for heterogeneity in studies and, if necessary, we performed sensitivity analyses examining the effects of excluding study subgroups, e.g. those studies with low methodological quality.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-03-18 08:45:37 +0000" MODIFIED_BY="Finola M Delamere">
<SEARCH_RESULTS MODIFIED="2008-04-29 13:58:26 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We identified 45 possible studies, of which 38 were RCTs; 41 were fully published papers,2 letters to the editor and 2 papers presented at meetings (1 of which was not published). One paper was in Japanese and the data extraction was kindly performed by YO. The full text or abstract of each trial was examined independently by two authors (AB &amp; HCW).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-05-12 16:18:20 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Twenty one studies with 1018 participants were included in this review and are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. All studies were randomised controlled trials; 12 parallel group, 4 cross-over and 5 within-patient studies. The studies involved sample sizes between 4 and 186 participants and all that specified the setting (2 did not) were conducted in secondary care. Eleven of the studies were conducted in Western Europe, five in North America and five elsewhere in the world. Five of the studies were conducted using multiple centres, 14 were single centre and 2 did not specify. Three studies looked specifically at children and two specifically at adults, seven included both and in nine studies it was not clear. All the studies included both males and females.</P>
<P>The included studies fell into seven very broad categories;</P>
<P>1. Oral antibiotics (three RCTs),<BR/>2. Antibacterial soaps (one RCT),<BR/>3. Topical steroid plus an antibiotic and an antifungal (one RCT),<BR/>4. Antibacterial bath additives (two RCTs),<BR/>5. Topical antiseptic/antibiotic (four RCTs),<BR/>6. Topical steroid plus antibiotic (nine RCTs),<BR/>7. Silver impregnated textiles (one RCT).</P>
<P>Control groups most commonly received vehicle alone (four RCTs) or a placebo tablet (three RCTs) with the exception of those studies involving steroid antibiotic combinations in which case the controls used a topical steroid without the antibiotic added (ten RCTs). The studies had multiple stated outcomes, a number of which were not reported in the results. Six studies intended to report on global improvement, seven on adverse events. A large number of studies looked at microbiological data including sensitivity of or resistant organisms (4 RCTs), isolation rates (10 RCTs) and colony counts (13 RCTs) of <I>S. aureus</I>. Some studies assessed outcome based on a published named scale including SCORAD (SCORing Atopic Dermatitis) (three RCTs), EASI (Eczema Area &amp; Severity Index) (one RCT) and SASSAD (Six Area, Six Sign Atopic Dermatitis) (one RCT) (<LINK REF="REF-Schmitt-2007" TYPE="REFERENCE">Schmitt 2007</LINK>). The majority used an arbitrary, unvalidated scale to assess efficacy (nine RCTs).</P>
<P>We did not consider that any of the first five categories, or the seventh category, had studies sufficiently similar to pool. In the sixth category four papers reported within-patient studies or parallel group studies of potent steroids plus antibiotic that were pooled in groups of two (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>; <LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>; <LINK REF="STD-Hjorth-1985" TYPE="STUDY">Hjorth 1985</LINK>; <LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>). For the initial pooling we did not take into consideration whether it was infected or non-infected atopic eczema that was being treated.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial periods</HEADING>
<P>Only 1 of the 21 included studies (<LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>) was of greater than a month's duration and therefore considered a reasonable time to reflect disease chronicity. We considered the remainder to provide short-term data. <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK> did report data from 56 days after the trial period had ended, though the intervention itself was for a short-term only.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-05-12 15:12:48 +0100" MODIFIED_BY="Finola M Delamere">
<P>We excluded 24 studies and their details can be found in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Seven were not RCTs, nine were excluded as they did not provide separate results for atopic eczema (only "steroid responsive dermatoses" in general), one was an in-vitro study, one a duplicate study and six were excluded as they only compared anti-staphylococcal agents against each other or against an inappropriate control. On this final point, it was agreed that a vehicle was not an appropriate comparator for a steroid/antibiotic combination as it is well recognised that topical steroids are an effective treatment for inflamed eczema and thus one could not establish whether it is the addition of the antibiotic, or the steroid itself that has efficacy. This is not a change from the original protocol, rather a clarification of the inclusion criteria.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-04-29 13:59:54 +0100" MODIFIED_BY="Diane A  Horsley">
<P>The overall methodological quality of the trials was poor. Please see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for further information on the quality of the included studies. Since no meta-analyses were performed involving more than two studies, sensitivity analysis based on methodological quality was not performed. </P>
<ALLOCATION MODIFIED="2008-05-12 15:15:03 +0100" MODIFIED_BY="Finola M Delamere">
<P>In 17 of the 21 trials in this review the method of randomisation was not described at all or was unclear. <LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK> used a computer generated random code, <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK> drew lots, <LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK> used a randomisation list created by an independent biometrician using statistics software and <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK> used a computer generated list in blocks of four. In only three of the trials have the trial authors clearly demonstrated that concealment of allocation was adequate; one study had the medication pre-prepared by the drug company (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>), one had identical tubes pre-prepared by pharmacy (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>) and one had concealed packs in pharmacy (<LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-04-29 14:47:36 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Blinding of outcome assessment was attempted for most of the trials. However, the method as to how this was done was generally unclear and poorly described. In only one study were the authors (AB &amp; HCW) convinced that everyone (the participants, clinicians and outcome assessors) was adequately blinded (<LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) and in only three others that the outcome assessor was adequately blinded (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>; <LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK>; <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>). Of studies in which patient assessment of outcome was included only five had adequately described blinding of the participants (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>; <LINK REF="STD-Schempp-2003" TYPE="STUDY">Schempp 2003</LINK>; <LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>; <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-05-12 16:19:36 +0100" MODIFIED_BY="Diane A  Horsley">
<P>In many of the trials analysis of outcome was carried out only on those participants who completed the trial. Only 6 of the 21 trials were analysed by intention to treat (<LINK REF="STD-Hjorth-1985" TYPE="STUDY">Hjorth 1985</LINK>; <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>; <LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>; <LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>; <LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>). Six trials definitely had no losses to follow up. Eight trials were either not clear as to how many patients were lost to follow up or did not specify any reasons why they were (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>; <LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>; <LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>; <LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>; <LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK>; <LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>; <LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK>; <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK>). One study (<LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>) was particularly unclear; it reported that 180 were enrolled, but only 143 were recruited. It appeared that the final number recruited depended on an assessment, but this was not clear. See also <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-04-29 14:03:03 +0100" MODIFIED_BY="Diane A  Horsley">
<P>The abstract of one study (<LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>) concludes that daily bathing with an antibacterial soap provides clinical improvement, but the actual results in each group along with the significant values are not given; the results are plotted on a graph with very different baselines in each group with improvement looking parallel. </P>
<P>
<LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK> reported that "the most significant result" of the study was a significant change in score from baseline at weeks two and four in the treatment group. However, the correct statistic was not reported i.e. the difference between the change in score for the two treatments.</P>
<P>In the summary, despite having results that are not statistically significant, <LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK> states that "combination therapy reduced the mean scores for infection, inflammation and overall severity to a greater extent than the antibiotics or corticosteroid alone." </P>
<P>There was no significant difference in the stated global outcome of <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK>, however they performed a post hoc subgroup analysis in which they found that participants with specific clinical scores fared better in the treatment group compared to the control. They reported this in the abstract and used it to suggest, as one of their main conclusions, that early combined treatment is beneficial to that specific subgroup.</P>
<P>
<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK> claimed that use of the silver textiles "led to an impressive improvement of atopic dermatitis," but the evidence provided was not sufficient to back up this claim.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2008-05-12 15:20:19 +0100" MODIFIED_BY="Finola M Delamere">
<P>A concern with the <LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK> study is that the treatment arm (with silver textiles) used 135 g of topical steroid whereas the control arm used only 13 g which suggests that unblinding may have taken place.</P>
<P>We were unable to assess for publication bias as there were not enough studies to perform a funnel plot. There were a couple of duplicate publications. Identical results were published by <LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK> and <LINK REF="STD-Zienicke-1993" TYPE="STUDY">Zienicke 1993</LINK>. <LINK REF="STD-Schempp-2003" TYPE="STUDY">Schempp 2003</LINK> also published an identical study in German (<LINK REF="STD-Schempp-2003a" TYPE="STUDY">Schempp 2003a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Certainty of diagnosis</HEADING>
<P>Six of the 21 included studies used the Hanifin and Rajka definition or the UK modification for the diagnosis of atopic eczema (<LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK>; <LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>; <LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>; <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK>) whereas the remaining 15 relied on the diagnosis being made by a physician. Only two studies specified infected atopic eczema in their inclusion criteria (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>, <LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>). A number of studies had inclusion criteria such as "super infected" or "acute" atopic eczema, but these descriptions were not defined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparison for severity</HEADING>
<P>Eight of the 21 did not provide data for baseline comparison (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>; <LINK REF="STD-Fattah-1976" TYPE="STUDY">Fattah 1976</LINK>; <LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>; <LINK REF="STD-Hjorth-1985" TYPE="STUDY">Hjorth 1985</LINK>; <LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK>; <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>; <LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>; <LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>). In <LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK> the "pre-treatment severity scores" were not the same in the two treatment groups of the cross-over study (69.9 +/- 6.9, 59.5 +/- 6.4) and in <LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK> the "total clinical score" was not comparable; control being 6.4 +/- 3.8 and intervention 9.6 +/- 2.6. In the other studies, severity of the atopic eczema was comparable at baseline. In one of the studies (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) the baseline SCORAD was so different (74.6 in the treatment group and 51.9 in the control) that it affected the outcome of the study and thus the unadjusted results should be interpreted with caution. Disease duration was only reported in four of the studies (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>; <LINK REF="STD-Fattah-1976" TYPE="STUDY">Fattah 1976</LINK>; <LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) and previous responses to treatment were not generally reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparison of presence of S Aureus</HEADING>
<P>Six of the studies did not include a baseline comparison of the presence of <I>S. aureus</I> (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>; <LINK REF="STD-Fattah-1976" TYPE="STUDY">Fattah 1976</LINK>; <LINK REF="STD-Hjorth-1985" TYPE="STUDY">Hjorth 1985</LINK>; <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>; <LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>; <LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK>). <LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK> did record the presence or absence of staphylococcus, but did not specify whether it was <I>S. aureus,</I> or another strain such as<I> S. epidermidis</I>. The remainder of the studies did include baseline comparisons which were similar, with the exception of <LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK> and <LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amount of topical steroid used during study period</HEADING>
<P>This was generally not reported. In <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK> no topical corticosteroid was permitted during the trial period. <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK> did record a striking difference in the amount used both at the end of the trial period (day 28) in which the intervention (flucloxacillin) group used a mean of 61.0 g/2 weeks (95% CI 26.3, 95.7) and the placebo group only 29.2 g/2 weeks (95% CI 18.6, 39.7), and at 56 days post treatment the intervention group had used 50.2 g/2 weeks (95% CI 18.4, 82.1) and the placebo group 33.4 g/2 weeks (95% CI 10.3, 56.6). <LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK> reported that there was no significant difference in the amount of topical steroid used between groups (p = 0.86). Another study in which the amount of topical steroid used was recorded was <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK> in which an astonishing 462 g was used in the intervention group and 349 g in the control group in 2 weeks. This is substantially different from normal practice and would make the results from this study difficult to interpret for use in a clinical setting. There was no limitation on the amount of topical steroid used in one study (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) which resulted in an elevated positive result in the treatment group which used more than ten times the amount of steroid as in the control.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-12 15:38:13 +0100" MODIFIED_BY="Finola M Delamere">
<P>Please see table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Subgroup analysis was not performed as there were no appropriate studies to pool.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Oral Antibiotics- three RCTs</HEADING>
<P>We included 3 RCTs; one cross over study of 20 participants (<LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>) and 2 parallel studies (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>Two studies reported global degree of improvement in signs and symptoms as rated by the medical practitioner (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>). One study of 46 participants (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) found a significant improvement in the placebo group compared to flucloxacillin (RR 2.49; 95% CI 1.27, 4.89) [<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>]. The other study of 33 participants (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>) found a non significant improvement in the cefadroxil group for global outcome (RR 0.40; 95% CI 0.13, 1.24) [<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>]. One study (<LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>) reported no change in clinical severity, but provided no data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</HEADING>
<P>One study reported no adverse events (<LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>). Pooled analysis from two studies (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) showed no significant differences for adverse events requiring withdrawal (RR 1.64; 95%CI 0.21,12.78) [<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Minor patient reported adverse events.</HEADING>
<P>This included mild skin irritation not sufficient to require cessation of treatment.</P>
<P>No study reported minor patient adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Emergence of antibiotic resistant micro-organisms.</HEADING>
<P>See long-term results.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Tertiary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global changes in composite rating scales, using a published named scale.</HEADING>
<P>No data were provided for this outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Changes in the individual signs of atopic eczema as assessed by a physician.</HEADING>
<P>Two studies (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>; <LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) found no significant difference in erythema in the control groups compared to oral antibiotic (MD 0.40; 95% CI -0.03, 0.83) [<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>], (RR 0.93; 95% CI 0.38, 2.28) [<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>]. The two studies could not be pooled because one used a continuous and the other a dichotomous measure (score). One study (<LINK REF="STD-Weinberg-1992" TYPE="STUDY">Weinberg 1992</LINK>) found significantly fewer clinically apparent infection in the treatment group at the end of the study compared to control (RR 0.06; 95%CI 0.00, 0.94) [<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Duration of remission and/or prevention of subsequent flares.</HEADING>
<P>No results were given for this outcome of interest.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.</HEADING>
<P>One study (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) found significantly fewer people had <I>S. aureus</I> isolated in the flucloxacillin group compared to the control (RR 0.68; 95% CI 0.49, 0.95) [<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>], though the mean log of <I>S. aureus</I> counts was not significantly reduced in the treatment group compared to placebo (MD -1.4; 95% CI -3.09, 0.29) [<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>]. The isolation rates of <I>S. aureus</I> from affected skin reduced from 24/24 patients to 15/22 in the flucloxacillin group and from 24/25 to 22/24 in the placebo group as reported in the text.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus.</HEADING>
<P>One study (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) found a non significant reduction in the log <I>S. aureus</I> counts/cm<SUP>2</SUP> in the flucloxacillin group compared to placebo, though this may well have been significant had the baselines been comparable. Another study (<LINK REF="STD-Boguniewicz-2001" TYPE="STUDY">Boguniewicz 2001</LINK>) suggested that addition of an antibiotic resulted in a reduction in colony counts, however when the antibiotic was discontinued the skin was quickly recolonised.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Minor patient reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Emergence of antibiotic resistant micro-organisms.</HEADING>
<P>Only one study (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) reported that the number of methicillin resistant strains (MRSA) increased in the treatment group up until 14 days after treatment, but did not give individual patient data. Any increase in the number of MRSA had returned to almost baseline at day 56.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Tertiary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global changes in composite rating scales, using a published named scale.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Changes in the individual signs of atopic eczema as assessed by a physician.</HEADING>
<P>One study reported no significant difference in erythema at 56 days post treatment with oral flucloxacillin compared to placebo (MD -0.10; 95% CI -0.59, 0.39) [<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Duration of remission and/or prevention of subsequent flares.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus.</HEADING>
<P>In one study (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) bacterial counts returned to almost pre-treatment levels by 14 days after completion of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Antibacterial soaps- one RCT</HEADING>
<P>One very poor quality study compared 1.5% Triclocarban soap versus placebo in 49 adults with moderate severity atopic eczema (<LINK REF="STD-Breneman-2000" TYPE="STUDY">Breneman 2000</LINK>) provided little or no data to substantiate claims of efficacy. Some data were provided in graphs, however this was impossible to interpret. No data in relation to our outcomes were given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Topical steroid plus an antibiotic and antifungal- one RCT</HEADING>
<P>
<LINK REF="STD-Fattah-1976" TYPE="STUDY">Fattah 1976</LINK> compared 0.1% halcinonide with neomycin plus nystatin versus 1% hydrocortisone cream in a right-to-left study of eight people with steroid responsive dermatoses. Only results for those with atopic eczema were considered (n=4).</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>One study showed no significant difference in global outcome; out of a total of four participants three achieved a good or excellent response with the combination treatment and two with hydrocortisone alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
<P>No results were reported for any of the other outcomes of interest.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<P>There were no long-term data presented relevant to our outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Antibacterial bath additives - two RCTs</HEADING>
<P>Two studies compared a mineral oil based bath emollient (Oilatum) versus the same emollient incorporating triclosan and benzalkonium chloride (Oilatum Plus) bath emollient; one was a cross-over study of 26 children (<LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>) and the other a parallel group study of 15 children and adults (<LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>). Results for the first period of the cross-over study (<LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>) were not given which precluded the pooling of results, also no numbers were given in the text and extracting data from the figures was not possible.</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>One study (<LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>) suggested, in the text, no statistically significant difference between the treatment groups. The results given are difficult to interpret since baseline data were absent and no firm numbers were given for the individual patient groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
<P>No results were reported for any of the other outcomes of interest.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<P>There were no long-term data presented relevant to our outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Topical antiseptic/antibiotic- four RCTs</HEADING>
<P>Four different studies compared very different interventions versus placebo. One cross-over study of 45 participants (<LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK>) and three right-and-left comparisons (<LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK> [n=15], <LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK> [n=17], <LINK REF="STD-Schempp-2003" TYPE="STUDY">Schempp 2003</LINK> [n=18]). Pooling of data was not possible for these four studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>No numbers were given, but <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK> reported that there was a statistically significant improvement in the povidone iodine group for appearance of skin lesions, however no between group analysis was done.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Minor patient reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Emergence of antibiotic resistant micro-organisms.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Tertiary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global changes in composite rating scales, using a published named scale.</HEADING>
<P>
<LINK REF="STD-Schempp-2003" TYPE="STUDY">Schempp 2003</LINK> suggested a significant reduction in modified SCORAD in the Hyperforin 1.5% group of 6.5 compared to 2.5 in the control. However, data were not available for the number of patients in each group and therefore interpretation of these data was limited.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Changes in the individual signs of atopic eczema as assessed by a physician.</HEADING>
<P>
<LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK> compared 0.2% farnesol + 5% xylitol cream vs placebo and stated that scores of dryness and scaling were significantly improved in both groups, but no data were provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Duration of remission and/or prevention of subsequent flares.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.</HEADING>
<P>For the first period of the cross-over study (<LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK>) there was a significant reduction in <I>S. aureus </I>colonisation in the mupirocin group compared with the control group (RR 0.06; 95% 0.01, 0.44) [<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus.</HEADING>
<P>No numbers were given, but <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK> reported that there was a statistically significant improvement in the povidone iodine group for <I>S. aureus</I> colony counts, however no between group analysis was done. <LINK REF="STD-Masako-2005b" TYPE="STUDY">Masako 2005b</LINK> reported that at end of treatment there was a significant difference in the number of <I>S. aureus</I> in favour of 0.2% farnesol + 5% xylitol cream compared with placebo.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<P>There were no long-term data presented relevant to our outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Topical corticosteroids plus antibiotic- nine RCTs</HEADING>
<P>There were 9 RCTs, with a total of 677 participants, comparing corticosteroid plus antibiotic versus corticosteroid; all were of poor methodological quality with the exception of 1 with 44 participants (<LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>). There were a number of different corticosteroid potencies and the majority added an antibiotic to a corticosteroid and compared it to the same corticosteroid. Two studies (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK> [n14]; <LINK REF="STD-Hjorth-1985" TYPE="STUDY">Hjorth 1985</LINK> [n=60]) gave no data for the outcomes of interest.</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>One study (<LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>) compared prednicarbate 0.25% cream plus didecyldimethyl - ammonium chloride 0.25% to prednicarbate 0.25% cream, in 143 participants, and found no significant difference in global outcome at the end of treatment (RR 0.64; 95% CI 0.25, 1.68) [<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>]. One study comparing betamethasone valerate plus gentamicin cream vs betamethasone valerate cream vs gentamicin cream in 79 participants (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>) showed no significant difference in global outcome (RR 0.31; 95% CI 0.07, 1.35) [<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>]. When these latter two studies were pooled the combination treatment did not show a significant improvement compared to steroid alone in infected/heavily colonised eczema (RR 0.52; 95% CI 0.23, 1.16) [<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>]. <LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK> compared the super-potent clobetasol versus the potent betamethasone plus neomycin cream, in 28 individuals, and found a significant improvement in global outcome in favour of clobetasol using a subjective interval scale self-evaluation (MD 1.2; 95% CI 0.25, 2.15) [<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</HEADING>
<P>Pooled results from 2 studies of 198 participants (<LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) showed no significant difference in adverse events requiring withdrawal from treatment (RR 0.49; 95% CI 0.09, 2.78) [<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Minor patient reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</HEADING>
<P>Pooled results from two studies (<LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) showed significantly fewer minor adverse events not requiring withdrawal from treatment in the combination treatment group compared to the control, (RR 0.34; 95% CI 0.15, 0.77) [<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Emergence of antibiotic resistant micro-organisms.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Tertiary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global changes in composite rating scales, using a published named scale.</HEADING>
<P>One study (<LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) showed no significant difference in SCORAD at the end of treatment between 3% tetracycline plus 0.1% triamcinolone and 0.1% triamcinolone(MD -0.40; 95% CI -10.39, 9.59) [<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>]. <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK> reported that both hydrocortisone and mupirocin and hydrocortisone alone showed significant within group improvement in EASI (Eczema Area and Severity Index) scores, however at the end of treatment there was no significant difference in EASI scores (MD -1.08; 95% CI -2.51, 0.35) [<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Changes in the individual signs of atopic eczema as assessed by a physician.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Duration of remission and/or prevention of subsequent flares.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.</HEADING>
<P>In one study (<LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>) isolation of <I>S. aureus</I> in the prednicarbate 0.25% cream plus didecyldimethyl - ammonium chloride 0.25% group reduced from 47/69 to 5/69 and from 54/74 to 7/74 in the steroid only group as reported in the text. One study of 36 participants (<LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>) showed a significant reduction (85%) in the isolation of <I>S. aureus</I> when using the combination cream (Fluocinolone acetonide plus 0.5% neomycin sulphate) compared with fluocinolone acetonide cream alone (RR 0.32; 95% CI 0.11, 0.94) [<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>]. Pooled analysis from two studies (<LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>; <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) showed an 83% reduction in the isolation rate of <I>S. aureus</I> in the combination group compared to steroid alone at the end of treatment (RR 0.37; 95% CI 0.20, 0.69) [<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>]. <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK> reported that 89/119 people with eczema had <I>S. aureus</I> present in lesional skin at baseline and 41/119 in non-lesional skin, but no data for the end of the study, comparing hydrocortisone and mupirocin and hydrocortisone alone, other than a statement that there was no significant difference between experimental groups and control groups.</P>
<P>(e) Change in bacterial counts of <I>S. aureus</I>, i.e. an assessment of quantity of <I>S. aureus</I>.</P>
<P>In one study of 30 participants (<LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK>) both steroid plus antibiotic and steroid alone completely cleared <I>S. aureus</I> (presented as log counts).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<P>There were no long-term data presented relevant to our outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Silver impregnated textiles- one study</HEADING>
<P>One study of 30 participants compared silver impregnated underclothes with polyester underclothes (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner.</HEADING>
<P>One study (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) reported no significant difference in the overall disease control of atopic dermatitis in the silver textile group compared with the non-silver textile as assessed by the patient or their carer (RR 2.67; 95% CI 0.98, 7.22) [<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in Quality of Life questionnaires.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Minor patient reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Emergence of antibiotic resistant micro-organisms.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Tertiary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(a) Global changes in composite rating scales, using a published named scale.</HEADING>
<P>One study (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) reported a reduction in the median SCORAD from 74.6 to 29.95 in the silver group and from 51.9 to 48.2 in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Changes in the individual signs of atopic eczema as assessed by a physician.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(c) Duration of remission and/or prevention of subsequent flares.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.</HEADING>
<P>There were no results given for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus.</HEADING>
<P>In one study (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>) both groups showed a similar degree of reduction in <I>S. aureus</I> counts (MD 0.0; 95% CI -0.93, 0.93) [<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>].</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term:</HEADING>
<P>There were no long-term data presented relevant to our outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number needed to treat:</HEADING>
<P>It was deemed inappropriate to calculate the number needed to treat (NNT) for any of the interventions due to lack of significance of data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-03-14 15:01:06 +0000" MODIFIED_BY="Diane A  Horsley">
<SUMMARY_OF_RESULTS MODIFIED="2008-04-30 09:47:50 +0100" MODIFIED_BY="Finola M Delamere">
<P>None of the trials showed any clear benefit in terms of short-term eczema control for any of the interventions tested, although several interventions were associated with decreased numbers of <I>S. aureus</I> on the skin.</P>
<P>One poorly reported study (<LINK REF="STD-Schempp-2003" TYPE="STUDY">Schempp 2003</LINK>) suggested a significant reduction in eczema severity using a modified SCORAD (SCORing Atopic Dermatitis) rating scale when Hyperforin 1.5% cream was compared with placebo. Although this result is statistically significant, a median difference of four points on the modified SCORAD may not be clinically beneficial.</P>
<P>There was no clear evidence that the widely used topical steroid/antibiotic combinations were any better than the topical steroids used alone. A range of different potencies of topical steroid combined with an antibiotic have been appropriately compared to the same steroid. However, <LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK> compared the super-potent clobetasol versus the potent betamethasone plus neomycin, which is not a fair test. Not surprisingly, that study found a significant improvement in global outcome in the super-potent steroid group. Interestingly, <I>S. aureus</I> was completely cleared in both groups in that same study (<LINK REF="STD-Nilsson-1992" TYPE="STUDY">Nilsson 1992</LINK>), demonstrating that the use of topical steroids alone on eczematous skin will result in the reduction of <I>S. aureus</I>. This raises the question as to whether the addition of antibiotics to a topical preparation is justified in any clinical scenario.</P>
<P>Pooled analysis of two studies (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>; <LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>) found no significant difference in global outcome in steroid/antibiotic combinations compared to steroid alone in people with infected/heavily colonised eczema (RR 0.52; 95% CI 0.23, 1.16) [<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>]. There were significant differences between these studies, in particular one study used a medium potency steroid, prednicarbate (<LINK REF="STD-Korting-1994" TYPE="STUDY">Korting 1994</LINK>), and the other a potent steroid, betamethasone valerate (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>) and they both used different antibiotics, but as they were both in infected/heavily colonised eczema they were thought to be similar enough to pool.</P>
<P>There was no significant difference in adverse events requiring withdrawal from treatment when comparing topical steroid/antibiotic combinations (pooled results from two studies <LINK REF="STD-Ramsay-1996" TYPE="STUDY">Ramsay 1996</LINK> and <LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>). However, in one study (<LINK REF="STD-Schuttelaar-2005" TYPE="STUDY">Schuttelaar 2005</LINK>) there were fewer minor adverse events not requiring withdrawal from treatment in the combination treatment group compared to steroid alone. In that study participants in both treatment arms were instructed to apply substantially more topical treatment than would be expected in normal practice. Large quantities of topical steroids can induce a folliculitis and the antibiotic seemed to have a protective effect against this, thus explaining the fewer adverse events in those using the combination treatment.<BR/>
<BR/>In general, the reporting of adverse effects from the use of topical treatments was poor. Although those studies that did record them did not find many, supporting the notion that such topical treatments are generally well tolerated in people with eczema. One study (<LINK REF="STD-Polano-1960" TYPE="STUDY">Polano 1960</LINK>) concluded by not recommending the combination of neomycin with a topical steroid due to the risk of the development of sensitivity to the antibiotic.</P>
<P>Only one study reported on the emergence of resistant bacterial strains in the group treated with oral antibiotics. It is disappointing that so few studies looked at the development of resistant strains as one of the concerns of the potential over-use of antibiotic containing preparations is the development of bacterial resistance (<LINK REF="REF-El_x002d_Zimaity-2004" TYPE="REFERENCE">El-Zimaity 2004</LINK>, <LINK REF="REF-Ravenscroft-2000" TYPE="REFERENCE">Ravenscroft 2000</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2008-05-13 15:25:08 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Failure to demonstrate evidence that anti-staphylococcal interventions control eczema flares does not necessarily mean that they could not prevent further flares and contribute to long-term management in general. It is disappointing that no studies provided quality of life data and that so few made any attempt to examine the long-term effects of interventions.</P>
<P>It is also worth pointing out that in practice, most people with eczema will be using accessory care such as emollients or specific cleansing products and it would have been useful if studies had documented this.</P>
<P>Those studies that recorded whether the eczema was "clinically infected" did not make it clear what was meant by infection. Indeed, many of the "clinically" infected participants in one study (<LINK REF="STD-Wachs-1976" TYPE="STUDY">Wachs 1976</LINK>) were not infected according to microbiological criteria. It is already widely recognised that eczematous areas of the body are more colonised with <I>S. aureus</I> than non-eczematous and the results of a number of the studies were in agreement with this (<LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK>; <LINK REF="STD-Gong-2006" TYPE="STUDY">Gong 2006</LINK>).</P>
<P>The results of this review corroborate with both the NICE (<LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>) and the British Association of Dermatologists and the Primary Care Dermatology Society guidelines (<LINK REF="REF-PCDS-2003" TYPE="REFERENCE">PCDS 2003</LINK>) on the management of atopic eczema which state that the role of <I>S. aureus</I> as an important exacerbating factor in atopic eczema is a matter of debate, that oral antibiotics are often necessary in moderate to severe infection and that steroid-antibiotic combinations are effective in clinical practice although evidence for superiority in efficacy is lacking.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2008-05-12 15:55:59 +0100" MODIFIED_BY="Finola M Delamere">
<P>We included 21 randomised controlled trials involving 1018 participants. Quality of reporting was generally poor. Both studies of antibacterial bath additives were poorly reported (<LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>; <LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>). In <LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>, baseline data were absent and no clear data were given for the individual patient groups. The study by Holland et al (<LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>) was also poorly reported: no actual data were provided in the text and extracting data from the figures was not possible. Instead, only "P values" were given for individual groups, with no comparison across the two groups i.e. the key hypothesis under test in a comparative trial. Five other studies also failed to conduct appropriate between group comparisons in their analyses (<LINK REF="STD-Leyden-1977" TYPE="STUDY">Leyden 1977</LINK>; <LINK REF="STD-Lever-1988" TYPE="STUDY">Lever 1988</LINK>; <LINK REF="STD-Harper-1995" TYPE="STUDY">Harper 1995</LINK>; <LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>; <LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>).</P>
<P>It is also worth highlighting a major limitation of the study of silver impregnated textiles (<LINK REF="STD-Juenger-2006" TYPE="STUDY">Juenger 2006</LINK>). Although they reported a significant improvement in the treatment arm and not in the placebo (though not between groups), those using silver textiles used 135 g of topical steroid whereas those in the control arm used only 13 g, suggesting that all of the benefit could have been due to confounding from additional use of topical steroids.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2008-04-29 14:12:02 +0100" MODIFIED_BY="Diane A  Horsley">
<P>It is a possibility that not all relevant studies have been included in this review, and that we failed to find some unpublished trials. Every effort has been made to locate such studies, but some authors of older studies had deceased and many failed to respond to requests for additional information. Some studies containing potentially useful data on people with atopic eczema had to be excluded because their results were lumped together with other people with a range of other skin problems. Our pre-specified choice of clinically important outcomes also meant that some studies that failed to use a published rating scale were excluded. Some studies simply made up their own unvalidated composite scoring systems by pooling the individual signs of atopic eczema. Although many composite scales were used, very few studies reported improvement in individual clinical signs like redness or scaling, making it difficult to comment on which aspects of the condition improved.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2008-03-14 15:00:58 +0000" MODIFIED_BY="Diane A  Horsley">
<P>There have been no previous systematic reviews on this subject.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-12 16:03:09 +0100" MODIFIED_BY="Finola M Delamere">
<P>We found insufficient evidence to recommend the addition of oral antibiotics to the management of non-infected atopic eczema in children or adults and indeed one study (<LINK REF="STD-Ewing-1998" TYPE="STUDY">Ewing 1998</LINK>) suggested that the addition of long-term flucloxacillin may hinder improvement in eczema and lead to an increase in resistant strains. Whilst we have found insufficient evidence to make any firm recommendations on the use of oral antibiotics in the management of infected atopic eczema, the use of oral antibiotics under such circumstances is standard clinical practice and is recommended by bodies such as the National Institute for Health and Clinical Excellence (<LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). Whilst it would be helpful to see future studies quantifying the benefit of additional oral antibiotics in those with clinically infected atopic eczema with clear definitions of what constitutes clinically infected atopic eczema, we recommend that the use of appropriate oral antibiotics for overtly infected eczema should be continued, unless future evidence suggests otherwise.</P>
<P>There is evidence that topical antibiotics/antiseptics, whether used alone (four studies) or in combination with a topical steroid (nine studies), reduce colonisation of <I>S. aureus</I> in atopic eczema. However none of the 13 studies showed statistically significant effects to suggest that a reduction in <I>S. aureus</I> adds to the global improvement of atopic eczema. Their continued use has to be challenged, especially in view of the possibility that widespread use of topical antibiotics might contribute to antibiotic resistance in the community (<LINK REF="REF-El_x002d_Zimaity-2004" TYPE="REFERENCE">El-Zimaity 2004</LINK>).
<BR/>

<BR/>We found insufficient evidence to support the use of any of the other interventions that aim to reduce <I>S. aureus</I> in atopic eczema including antibacterial soaps (one study), antibacterial and antifungal agents both added to a topical steroid (one study), antiseptic bath additives (two studies), and silver textiles (one study). There is little evidence to justify their continued use. Whether they have a role to play in long-term control of eczema remains to be seen.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-12 16:00:42 +0100" MODIFIED_BY="Finola M Delamere">
<P>Very few randomised controlled trials have been conducted on the management of atopic eczema that include interventions that aim to reduce<I> S. aureus</I>. Those that have been done have been of poor methodological quality and have mostly been of short duration. Existing studies have tended to focus on microbiological outcomes rather than whether the intervention helps overall eczema severity or quality of life. </P>
<P>It is important that any future studies clearly define what they mean by "infected eczema." Although studies have failed to show any benefit of topical steroid/antibiotic combinations for clinically uninfected eczema, there is still a need for a large, good quality study comparing steroid plus topical antibiotic versus steroid alone in patients with clinically infected eczema, and this ideally ought to be combined with long-term follow-up. There is also a need for a good quality study comparing oral antibiotic plus topical steroid versus topical steroid alone in clinically infected eczema. </P>
<P>There is also a need to more clearly define study participants, including those who fail to respond to conventional treatments, or who are prone to recurrent infected eczema flares, as such a subgroup may benefit from anti-staphylococcal treatments. Studies thus far have failed to address whether the reduction of <I>S aureus</I> has any impact on the long-term reduction of flares. We would recommend that future studies evaluating anti-staphylococcal measures in people with atopic eczema include long-term outcomes such as number of flares or duration of remission in addition to short-term control. Future studies may also choose to standardise accessory care, such as emollients or cleansing agents, or if wishing to have a more pragmatic approach at least to document patients' use of such accessory care.
<BR/>

</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-04-29 15:59:56 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Dr Finola Delamere for performing the searches on numerous occasions over the past three years and inserting the search results into the review.<BR/>Dr Yukihiro Ohya who extracted the data from the Japanese language paper (<LINK REF="STD-Hizawa-1998" TYPE="STUDY">Hizawa 1998</LINK>).<BR/>Dr Vivien Weston for help with the interpretation of the microbiological data.<BR/>Dr Richard Williams and Ms Jacqueline Page for help with the development of the protocol previously published.<BR/>The editorial base would like to thank the following people who were the external referees for this review:<BR/>Pieter Jan Coenraads and Alain Taieb (content experts) and Mrs Shirley Manknell (consumer).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-04-04 20:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Draft protocol: JR with contributions from all<BR/>Run search: JR, FD, AB<BR/>Identify relevant titles and abstracts from searches i.e. broad screen: JR, AB, HCW<BR/>Obtain copies of trials: JR, AB<BR/>Select which trials to include: AB, JR, HCW, FBH<BR/>Extract data from trials: AB, HCW, FBH<BR/>Enter data into RevMan: AB, FBH<BR/>Carry out analysis: AB, FBH<BR/>Interpret analysis: AB, FBH, HCW<BR/>Draft final review: AB, FBH<BR/>Advice on final review: HCW</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-05-12 14:40:33 +0100" MODIFIED_BY="Finola M Delamere">
<P>We have changed the title of this review to 'Interventions to reduce Staphylococcus aureus in the management of atopic eczema'. In the protocol it was 'Interventions to reduce Staphylococcus aureus for atopic eczema'. We made this change in response to a comment from an external referee.</P>
<P>In the Background section under 'Description of the intervention' we have added a few sentences to the beginning of this section and a slight change of wording in the section 'How the intervention might work'.</P>
<P>Under 'Objectives' we have changed the text from 'To assess the efficacy and possible adverse effects of interventions to reduce S. aureus for treating atopic eczema' to 'To assess the effects of interventions to reduce <I>S. aureus</I> for treating atopic eczema'.</P>
<P>Under 'Types of interventions' in the review text we have added the following:<BR/>Antibacterial soaps, topical steroid plus antibiotic and antifungal agent, antibacterial bath additives and silver impregnated textiles.</P>
<P>Under 'Types of outcome measures' we have omitted the secondary outcome listed in the protocol 'we will report on skin irritation separately as it is a common occurence' from the review. We have explained this in the Methods section under 'Data extraction and management' as have the definitions of short-term benefit and long-term benefit.</P>
<P>Also under 'Measures of treatment effects' we have analysed the results have been analysed as risk ratios rather than odds ratios as was planned in the protocol, this is in line with Cochrane Skin Group policy and has been explained in the text.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P>The lead reviewer changed from JR to AB in 2004 and this has been reflected in the methods section. In March 2006 FB-H joined the review team.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-13 15:24:49 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDIES MODIFIED="2008-05-06 15:47:39 +0100" MODIFIED_BY="Diane A  Horsley">
<INCLUDED_STUDIES MODIFIED="2008-05-06 15:39:27 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDY DATA_SOURCE="PUB" ID="STD-Boguniewicz-2001" MODIFIED="2008-04-02 16:26:44 +0100" MODIFIED_BY="[Empty name]" NAME="Boguniewicz 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-04-02 16:26:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DYM</AU>
<TI>Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>4</NO>
<PG>651-2</PG>
<IDENTIFIERS MODIFIED="2008-03-18 12:05:31 +0000" MODIFIED_BY="Diane A  Horsley"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breneman-2000" NAME="Breneman 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breneman DL, Hanifin JM, Berge CA, Keswick BH, Neumann PB</AU>
<TI>The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis</TI>
<SO>Cutis</SO>
<YR>2000</YR>
<VL>66</VL>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ewing-1998" NAME="Ewing 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ewing CI, Ashcroft C, Gibbs ACC, Jones GA, Connor PJ, David TJ</AU>
<TI>Flucloxacillin in the treatment of atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>138</VL>
<PG>1022-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fattah-1976" NAME="Fattah 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fattah AA, El Shiemy S, Faris R</AU>
<TI>A comparative clinical evaluation of a new topical steroid "Halcinonide" and hydrocortisone in steroid responsive dermatoses</TI>
<SO>Journal of International Medical Research</SO>
<YR>1976</YR>
<VL>4</VL>
<PG>228-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gong-2006" MODIFIED="2008-05-06 15:39:27 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Gong 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-06 15:39:27 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, et al</AU>
<TI>Skin colonisation by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>155</VL>
<PG>680-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harper-1995" NAME="Harper 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Harper J</AU>
<TI>Double-blind comparison of an antiseptic oil-based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema</TI>
<SO>The bacterology of eczema</SO>
<YR>1995</YR>
<ED>Lever R, Levy J</ED>
<PB>The Royal Society of Medicine Press Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hizawa-1998" NAME="Hizawa 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hizawa T, Sano H, Endo K, Fukuzumi T, Kataoka Y, Aoki T</AU>
<TI>Is povidone-iodine effective to the lesions of atopic dermatitis</TI>
<SO>Skin Research</SO>
<YR>1998</YR>
<VL>40 (suppl. 20)</VL>
<PG>134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjorth-1985" NAME="Hjorth 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hjorth N, Schmidt H, Thomsen K</AU>
<TI>Fusidic acid plus betamethasone in infected or potentially infected eczema</TI>
<SO>Pharmacotheraputica</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holland-1995" NAME="Holland 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Holland KT, Bojar RA, Cunliffe WJ</AU>
<TI>A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds</TI>
<SO>The bacteriology of eczema</SO>
<YR>1995</YR>
<ED>Lever R, Levy J</ED>
<PB>The Royal Society of Medicine Press Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juenger-2006" NAME="Juenger 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Juenger M, Ladwig A, Staecker S, Arnold A, Kramer A, Daeschlein G, et al</AU>
<TI>Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD)</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>4</NO>
<PG>739-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korting-1994" NAME="Korting 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Korting HC, Zienicke H, Braun-Falco O, Boek K, Milbradt R, Nolting S, et al</AU>
<TI>Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?</TI>
<SO>Infection</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>6</NO>
<PG>390-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lever-1988" NAME="Lever 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lever R, Hadley K, Downey D, Mackie R</AU>
<TI>Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy</TI>
<SO>British Journal of Dermatology</SO>
<YR>1988</YR>
<VL>119</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leyden-1977" NAME="Leyden 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leyden JJ, Kligman AM</AU>
<TI>The case for steroid-antibiotic combinations</TI>
<SO>British Journal of Dermatology</SO>
<YR>1977</YR>
<VL>96</VL>
<PG>179-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masako-2005b" NAME="Masako 2005b" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Masako K, Yusuke K, Hideyuki I, Atsuko M, Yoshiki M, Kayoko M, et al</AU>
<TI>A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin</TI>
<SO>Journal of Dermatological Science</SO>
<YR>2005</YR>
<VL>38</VL>
<PG>207-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1992" NAME="Nilsson 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson EJ, Henning CG, Magnusson J, Sundsvall BS</AU>
<TI>Topical corticosteroids and Staphylococcus aureus in atopic dermatitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1992</YR>
<VL>27</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polano-1960" NAME="Polano 1960" YEAR="1960">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Polano MK, De Vries HR</AU>
<TI>Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments</TI>
<SO>Dermatologica</SO>
<YR>1960</YR>
<VL>120</VL>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsay-1996" MODIFIED="2008-03-18 12:06:48 +0000" MODIFIED_BY="Diane A  Horsley" NAME="Ramsay 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-03-18 12:06:48 +0000" MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P</AU>
<TI>The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>Suppl. 1</NO>
<PG>S15-S22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schempp-2003" NAME="Schempp 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schempp CM, Hezel S, Simon JC</AU>
<TI>Topical treatment of atopic dermatitis with St John's wort cream - a randomized, placebo controlled, double blind half-side comparison</TI>
<TO>Behandlung der subakuten atopischen Dermatitis mit Johanniskraut-Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign</TO>
<SO>Hautarzt</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>248-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schempp CM, Windeck T, Hezel S, Simon JC</AU>
<TI>Topical treatment of atopic dermatitis with St John's wort cream - a randomized, placebo controlled, double blind half-side comparison</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10 (supplement IV)</VL>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schuttelaar-2005" MODIFIED="2008-03-18 12:07:41 +0000" MODIFIED_BY="Diane A  Horsley" NAME="Schuttelaar 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Schuttelaar M-LA, Coenraads P-J</AU>
<TI>A randomised, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis</TI>
<SO>Journal of the European Academy of Dermatology</SO>
<YR>2008</YR>
<VL>In press</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wachs-1976" NAME="Wachs 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wachs GN, Maibach HI</AU>
<TI>Co-operative double-blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1976</YR>
<VL>95</VL>
<PG>323-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-1992" MODIFIED="2008-04-02 16:28:47 +0100" MODIFIED_BY="[Empty name]" NAME="Weinberg 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-04-02 16:28:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg E, Fourie B, Allmann B, Toerien A</AU>
<TI>The use of cefadroxil in superinfected atopic dermatitis</TI>
<SO>Current Theraputic Research</SO>
<YR>1992</YR>
<VL>52</VL>
<NO>5</NO>
<PG>671-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-06 15:46:36 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDY DATA_SOURCE="PUB" ID="STD-Bjornberg-1975" NAME="Bjornberg 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjornberg A, Hellgren L, Nygren B</AU>
<TI>Diproderm with Gentamicin - a new very potent steroid ointment in infected eczema</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>4</NO>
<PG>556-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breneman-1990" NAME="Breneman 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breneman DL</AU>
<TI>Use of mupiricin ointment in the treatment of secondarily infected dermatoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>5</NO>
<PG>886-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1973" NAME="Carpenter 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter CL, Jolly HW, McCormick GE, Schneiderman RN, Thompson JG</AU>
<TI>Combined steroid-antiinfective topical therapy in common dermatoses: a double-blind, multicenter study of iodochlorhydroxyquin-hydrocortisone in 277 patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>9</NO>
<PG>650-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1974" NAME="Clark 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clark RF</AU>
<TI>The case for corticosteroid-antibiotic combinations</TI>
<SO>Cutis</SO>
<YR>1974</YR>
<VL>14</VL>
<PG>737-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1968" MODIFIED="2008-05-06 15:42:56 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Davis 1968" YEAR="1968">
<REFERENCE MODIFIED="2008-05-06 15:42:56 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis CM, Fulghum DD, Taplin D</AU>
<TI>The value of neomycin in a neomycin-steroid cream</TI>
<SO>JAMA</SO>
<YR>1968</YR>
<VL>203</VL>
<PG>136-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eaglstein-1977" NAME="Eaglstein 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eaglstein WH</AU>
<TI>Systemic antibiotic treatment of secondarily infected dermatitis</TI>
<SO>Archives of Dermatology</SO>
<YR>1977</YR>
<VL>113</VL>
<NO>10</NO>
<PG>1378-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gauger-2003" NAME="Gauger 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D</AU>
<TI>Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema</TI>
<SO>Dermatology</SO>
<YR>2003</YR>
<VL>207</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GP-medical-research" MODIFIED="2008-04-02 17:26:44 +0100" MODIFIED_BY="[Empty name]" NAME="GP medical research" YEAR="1967">
<REFERENCE MODIFIED="2008-04-02 17:26:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The G.P. Medical Research Unit</AU>
<TI>Treatment of eczemas and infected eczemas</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1967</YR>
<VL>21</VL>
<NO>10</NO>
<PG>505-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimata-1998" MODIFIED="2008-03-18 12:16:13 +0000" MODIFIED_BY="Diane A  Horsley" NAME="Kimata 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-03-18 12:16:13 +0000" MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimata H</AU>
<TI>Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>158</VL>
<PG>949-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-1969" NAME="Lloyd 1969" YEAR="1969">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd KM</AU>
<TI>The value of neomycin in topical corticosteroid preparations</TI>
<SO>Southern Medical Journal</SO>
<YR>1969</YR>
<VL>62</VL>
<PG>94-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masako-2005a" NAME="Masako 2005a" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Masako K, Hideyuki I, Shigeyuki O, Zenro I</AU>
<TI>A novel method to control the balance of skin microflora. Part 1. Attack on biofilm of Staphylococcus aureus without antbiotics</TI>
<SO>Journal of Dermatological Science</SO>
<YR>2005</YR>
<VL>38</VL>
<PG>197-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meenan-1988" MODIFIED="2008-04-02 17:32:50 +0100" MODIFIED_BY="[Empty name]" NAME="Meenan 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-04-02 17:32:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meenan FOC</AU>
<TI>A double-blind comparative study to compare the efficacy of Locoid C with Tri-adcortyl in chldren with infected eczema</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1988</YR>
<VL>42</VL>
<PG>200-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remitz-2001" MODIFIED="2008-04-02 17:33:38 +0100" MODIFIED_BY="[Empty name]" NAME="Remitz 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-04-02 17:33:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Remitz A, Kyllonen H, Granlund H, Reitamo S</AU>
<TI>Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>1</NO>
<PG>196-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rist-2001" MODIFIED="2008-04-02 17:35:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rist 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-04-02 17:35:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rist T, Parish LC, Capin LR, Sulica V, Bushnell WD, Cupo MA</AU>
<TI>A comparison of the efficacy and safety of mupirocin cream and cepalexin in the treatment of secondarily infected eczema</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2002</YR>
<VL>27</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salo-1988" MODIFIED="2008-04-02 17:37:03 +0100" MODIFIED_BY="[Empty name]" NAME="Salo 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-04-02 17:37:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salo OP, Gordin A, Brandt H, Antikainen R</AU>
<TI>Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1988</YR>
<VL>21 (Suppl. D)</VL>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sasai_x002d_Takedatsu-1997" NAME="Sasai-Takedatsu 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sasai-Takedatsu M, Kojima T, Yamamoto A, Hattori K, Yoshijima S, Taniuchi S, et al</AU>
<TI>Reduction of Staphylococcus aureus in atopic skin lesions with acid electrolytic water - a new therapeutic strategy for atopic dermatitis</TI>
<SO>Allergy</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>1012-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schempp-2003a" NAME="Schempp 2003a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schempp CM, Hezel S, Simon JC</AU>
<TI>Treatment of subacute atopic dermatitis with St John's wort cream</TI>
<TO>Behandlung der subakuten atopischen Dermatitis mit Johanniskraut-Creme</TO>
<SO>Hautarzt</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>248-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stalder-1992" MODIFIED="2008-04-02 17:37:25 +0100" MODIFIED_BY="[Empty name]" NAME="Stalder 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-04-02 17:37:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stalder JF, Fleury M, Sourisse M, Allavoine TH, Chalamet C, Brosset P, et al</AU>
<TI>Comparative effects of two topical antiseptics (chlorhexidine vs KMnO4) on bacterial skin flora in atopic dermatitis</TI>
<SO>Acta Dermato-Venereologica (Stockholm)</SO>
<YR>1992</YR>
<VL>71 Suppl. 176</VL>
<PG>132-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thaci-1999" NAME="Thaci 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thaci D, Kokorsch J, Kaufmann R</AU>
<TI>Fusidic aci/Betamethasone 17-valerate in potentially infected atopic dermatitis</TI>
<SO>Journal of the European Academy of Dermatology</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>3 (Suppl)</NO>
<PG>S163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theodoridis-1979" NAME="Theodoridis 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theodoridis A, Vagena A, Sivenas C, Capetanakis J</AU>
<TI>Evaluation of a topical steroid antibiotic combination (halcinonide-neomycin-amphotericin) in the treatment of cutaneous candidiasis and inflammatory dermatoses</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>10</NO>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weitgasser-1983" MODIFIED="2008-04-02 17:39:07 +0100" MODIFIED_BY="[Empty name]" NAME="Weitgasser 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-04-02 17:39:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weitgasser H, Schindlery C, Macarol V</AU>
<TI>A comparative multicentre trial of halometasone/triclosan cream and betamethasone diproprionate/gentamicin sulphate cream in the treatment of infected acute eczematous dermatitis</TI>
<SO>Journal of International Medical Research</SO>
<YR>1983</YR>
<VL>11 Suppl. 1</VL>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitefield-1998" NAME="Whitefield 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitefield M</AU>
<TI>Effectiveness of a new antimicrobial emollient in the management of eczema/dermatitis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilkinson-JD-1985" MODIFIED="2008-04-02 17:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson JD 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-04-02 17:40:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson JD, Leigh DA</AU>
<TI>Comparative efficacy of betamethasone and either fusidic acid or neomycin in infected or potentially infected eczema</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>38</VL>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilkinson-RD-1980" NAME="Wilkinson RD 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson RD, Collins JP, Raymond GP, Mailhot R, Perras MA, Ricard P</AU>
<TI>Therapy of infected dermatitis: comparative response to two corticosteroid antimicrobial creams</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>207-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zienicke-1993" MODIFIED="2008-05-06 15:46:36 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Zienicke 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-05-06 15:46:36 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zienicke H</AU>
<TI>Topical glucocorticoids and anti-infectives: a rational combination?</TI>
<SO>Current Problems in Dermatology</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>186-91</PG>
<ED>Korting HC, Maibach HI</ED>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-05-06 15:47:39 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDY DATA_SOURCE="PUB" ID="STD-Gauger-2006" MODIFIED="2008-05-06 15:47:07 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Gauger 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-06 15:47:07 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gauger A, Fischer S, Mempel M, Schaefer T, Foelster-Holst R, et al</AU>
<TI>Efficacy and functionality of silver coated textiles in patients with atopic eczema</TI>
<SO>Journal of the European Academy of Dermatology and Veneriology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>534-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-03-28 16:31:16 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2007" MODIFIED="2008-05-06 15:47:23 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Huang 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-05-06 15:47:23 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang SH, Lin YT, Chu CY, Lee CC, Liang TC, et al</AU>
<TI>Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Senti-2006" MODIFIED="2008-05-06 15:47:39 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Senti 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-06 15:47:39 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senti G, Steinmann LS, Fischer B, Kurman R, Storni T, Johansen P, et al</AU>
<TI>Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment</TI>
<SO>Dermatology</SO>
<YR>2006</YR>
<VL>213</VL>
<NO>3</NO>
<PG>228-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-13 15:24:49 +0100" MODIFIED_BY="Diane A  Horsley">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-13 15:24:49 +0100" MODIFIED_BY="Diane A  Horsley">
<REFERENCE ID="REF-Brown-2002" NAME="Brown 2002" TYPE="JOURNAL_ARTICLE">
<AU>Brown EM, Thomas P</AU>
<TI>Fusidic acid resistance in Staphylococcus aureus isolates</TI>
<SO>The Lancet</SO>
<YR>March 2, 2002</YR>
<VL>359</VL>
<PG>803</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-David-1986" NAME="David 1986" TYPE="JOURNAL_ARTICLE">
<AU>David TJ, Cambridge GC</AU>
<TI>Bacterial infection and atopic eczema</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Zimaity-2004" MODIFIED="2008-05-06 15:48:32 +0100" MODIFIED_BY="Diane A  Horsley" NAME="El-Zimaity 2004" TYPE="JOURNAL_ARTICLE">
<AU>El-Zimaity D, Kearns AM, Dawson SJ, et al</AU>
<TI>Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthern area</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2004</YR>
<VL>54</VL>
<PG>441-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emerson-1997" NAME="Emerson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Emerson RM, Williams HC, Allen BR</AU>
<TI>Severity distribution of atopic dermatitis in the community and its relationship to secondary referrals</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>139</VL>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanifin-1980" NAME="Hanifin 1980" TYPE="JOURNAL_ARTICLE">
<AU>Hanifin JM, Rajka G</AU>
<TI>Diagnostic features of atopic eczema</TI>
<SO>Acta Dermato-Venerologica (Stockholm)</SO>
<YR>1980</YR>
<VL>92</VL>
<PG>44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-04-29 10:06:25 +0100" MODIFIED_BY="Finola M Delamere" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>February 2008</YR>
<EN>5.0.0</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2008-04-29 10:06:12 +0100" MODIFIED_BY="Finola M Delamere"/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2008-05-06 15:49:05 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1994" NAME="Kay 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kay J, Gawkroger DJ, Mortimer MJ, Jaron AG</AU>
<TI>The prevalence of childhood atopic eczema in a general population</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leung-2000" NAME="Leung 2000" TYPE="JOURNAL_ARTICLE">
<AU>Leung YM</AU>
<TI>Atopic dermatitis: New insights and opportunities for therapeutic intervention</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>5</NO>
<PG>860-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leyden-1974" NAME="Leyden 1974" TYPE="JOURNAL_ARTICLE">
<AU>Leyden JJ, Marples R, Kligman M</AU>
<TI>Staphylococcus aureus in the lesions of atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1974</YR>
<VL>90</VL>
<PG>525-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McFadden-1993" NAME="McFadden 1993" TYPE="JOURNAL_ARTICLE">
<AU>McFadden JP, Noble WC, Camp RDR</AU>
<TI>Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin</TI>
<SO>British Journal of Dermatology</SO>
<YR>1993</YR>
<VL>128</VL>
<PG>631-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neame-1995" NAME="Neame 1995" TYPE="JOURNAL_ARTICLE">
<AU>Neame RL, Berth-Jones J, Kurinczuk JJ, Graham-Brown RAC</AU>
<TI>Prevalence of atopic dermatitis in Leicester: a study of methodology and examination of possible ethnic variations</TI>
<SO>British Journal of Dermatology</SO>
<YR>1995</YR>
<VL>132</VL>
<PG>772-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2007" NAME="NICE 2007" TYPE="OTHER">
<AU>National Collaborating Centre for Women's and Children's health</AU>
<TI>Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years</TI>
<SO>National Institute for Clinical Excellence</SO>
<YR>2007</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://www.nice.org.uk/guidance/index.jsp?action=download&amp;amp;o=38559"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-PCDS-2003" MODIFIED="2008-05-13 15:24:49 +0100" MODIFIED_BY="Diane A  Horsley" NAME="PCDS 2003" TYPE="OTHER">
<AU>Primary Care Dermatology Society and British Association of Dermatologists</AU>
<TI>Guidelines on the management of atopic eczema</TI>
<SO>http://www.bad.org.uk/healthcare/service/Eczema_11.03.03.pdf</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ravenscroft-2000" NAME="Ravenscroft 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ravenscroft JC, Layton A, Barnham M</AU>
<TI>Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>327-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reed-1999" NAME="Reed 1999" TYPE="JOURNAL_ARTICLE">
<AU>Reed J, Lyons M, Waghorn D, Wilkinson J</AU>
<TI>Fusidic acid resistance rates in South Buckinghamshire</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>141 (Suppl 55)</VL>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitt-2007" MODIFIED="2008-05-06 08:13:54 +0100" MODIFIED_BY="Finola M Delamere" NAME="Schmitt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt J, Langan S, Williams HC and the European Dermato-Epidemiology Network</AU>
<TI>What are the best outcome measurements for atopic eczema?- A systematic review</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>120</VL>
<PG>1389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson_x002d_Dent-2000" NAME="Simpson-Dent 2000" TYPE="JOURNAL_ARTICLE">
<AU>Simpson-Dent SL, Hunt SJ, Hardman C, Barrett S, Wakelin SH</AU>
<TI>Rates of fusidic acid resistance in paediatric dermatology patients - a 6-year study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>143 (Suppl 57)</VL>
<PG>123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stalder-1994" NAME="Stalder 1994" TYPE="JOURNAL_ARTICLE">
<AU>Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P</AU>
<TI>Local steroid therapy and bacterial skin flora in atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1994</YR>
<VL>131</VL>
<PG>536-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strange-1996" NAME="Strange 1996" TYPE="JOURNAL_ARTICLE">
<AU>Strange P, Skov L, Lisby S, Nielson PL, Baadsgaard O</AU>
<TI>Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis</TI>
<SO>Archives of Dermatology</SO>
<YR>1996</YR>
<VL>132</VL>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1985" NAME="White 1985" TYPE="JOURNAL_ARTICLE">
<AU>White MI, Noble WC</AU>
<TI>The cutaneous reaction to staphylococcal protein A in patients with atopic dermatitis or psoriasis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1985</YR>
<VL>113</VL>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1990" NAME="Williams 1990" TYPE="JOURNAL_ARTICLE">
<AU>Williams REA, Gibson AG, Aitchison TC, Lever R, Mackie RM</AU>
<TI>Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1990</YR>
<VL>123</VL>
<PG>493-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1992" NAME="Williams 1992" TYPE="JOURNAL_ARTICLE">
<AU>Williams HC</AU>
<TI>Is the prevalence of atopic dermatitis increasing?</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1994" NAME="Williams 1994" TYPE="JOURNAL_ARTICLE">
<AU>Williams HC, Burney PGJ, Pembroke AC, Hay RH</AU>
<TI>The UK Working Party's diagnostic criteria for atopic dermatitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1994</YR>
<VL>131</VL>
<NO>3</NO>
<PG>383-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1999" NAME="Williams 1999" TYPE="JOURNAL_ARTICLE">
<AU>Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al</AU>
<TI>Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>1</NO>
<PG>125-38</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-06 15:33:50 +0100" MODIFIED_BY="Diane A  Horsley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-05-06 15:28:58 +0100" MODIFIED_BY="Diane A  Horsley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-05-06 15:01:53 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Boguniewicz-2001">
<CHAR_METHODS>
<P>D: cross over<BR/>AC: not stated<BR/>RS: not stated<BR/>B: participant Y, clinician &amp; outcome assessor U<BR/>ITT +</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:01:53 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two care, two centres, USA<BR/>Incl: moderate - severe atopic dermatitis who had S aureus cultured from skin<BR/>Excl: overt skin infection<BR/>Age: 6 to 58<BR/>Duration: not stated<BR/>Randomised: 20<BR/>m/f: 9/11<BR/>Evaluable: 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-29 16:05:56 +0100" MODIFIED_BY="Diane A  Horsley">
<P>cefuroxime axetil orally (dose not stated) b.d. vs placebo orally b.d. given for two weeks each with one week washout inbetween</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Colony counts from two involved areas and inguinal area</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Outcomes not clear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:02:21 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Breneman-2000">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated<BR/>RS: not stated<BR/>B: participant Y, clinician U, outcome assessor U<BR/>ITT not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:02:13 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Setting not specified but conducted in conjunction with dept of dermatology in Cincinnati and Portland.<BR/>Incl: atopic dermatitis (Hanifin and Rajka criteria)<BR/>Excl: not stated<BR/>Age: mean 35 (male), 34.6 (female)<BR/>Duration: not stated<BR/>Randomised: 50<BR/>m/f: 15/35<BR/>Evaluable: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:02:21 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Soap containing triclocarban 1.5% vs placebo soap<BR/>Whole body to be washed at least daily for 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change from day 0 to day 14, 28, 42 as assessed by investigator (-5 = severe worsening, 5 = total clearing)<BR/>mean log colony forming units of S aureus at 0, 2, 4, 6, 9 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>participants also used standard moisturiser and 0.025% triamcinolone acetonide cream as required<BR/>Patient rating on itching, % with S aureus isolated and % of body surface area affected stated as outcomes, but not reported in results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:09:36 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Ewing-1998">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: by drug company<BR/>RS: not stated<BR/>B: Participant Y, clinician U, Outcome assessor U<BR/>ITT -<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:09:36 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, UK<BR/>Incl: Hanifin &amp; Rajka criteria atopic dermatitis with no sign of bacterial infection, treated with topical steroids, age 1 to 16 years, regular outpatient attendance<BR/>Excl: systemic steroids (past four weeks), systemic or topical antibiotics (past three weeks)<BR/>Age: FLX 7.5, P 5.2<BR/>Duration: not stated<BR/>Randomised: 50<BR/>m/f: not stated<BR/>Evaluable: 46</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 14:57:41 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Flucloxacillin (FLX) 250mg vs placebo qds for 4 weeks (dose halved for &lt; 10 yrs old)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 14:58:08 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Patient and assessor global degree of improvement<BR/>2. Emergence of resistant organisms<BR/>3. Physician rated severity of erythema (1 to 5)<BR/>4. Isolation of <I>S aureus</I> from affected and non-affected skin<BR/>5. mean log <I>S aureus</I> counts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:02 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Fattah-1976">
<CHAR_METHODS MODIFIED="2008-05-06 15:02:50 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: with-in patient study (left/right comparison)<BR/>AC: not stated<BR/>RS: not clear<BR/>B: participant N, clinician U, outcome assessor U<BR/>ITT not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:02 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, Egypt<BR/>Incl: atopic dermatitis<BR/>Excl: secondary infection<BR/>Age: not stated<BR/>Duration: mean 14.5 weeks<BR/>Randomised: four<BR/>m/f: not stated<BR/>Evaluable: four</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 10:01:35 +0100" MODIFIED_BY="Finola M Delamere">
<P>0.1% halcinonide cream with 0.25% neomycin and 100000u/g nystatin vs 1% hydrocortisone<BR/>both applied three times daily for not more than 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician assessed response to treatment made weekly</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The creams were different colours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:19 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Gong-2006">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: Not stated<BR/>RS: Not stated<BR/>B: participant Y, clinician Y, outcome assessor Y<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:19 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, multicentre, China<BR/>Incl: Hanifin &amp; Rajka criteria atopic dermatitis<BR/>Excl: severe fungal infection, other skin diseases which might disturb the diagnosis and treatment, other severe systemic infrction, pregnancy, lactation, diseases affecting immune function eg DM, AIDS, autoimmune disease, tumours, and severe heart, liver, kidney, mental diseases, treatment with systemic corticosteroids, immuno-suppressive agents last four weeks, allergy to drugs in the study, or in another study in the last four weeks.<BR/>Age: range 2 to 65<BR/>Duration: not stated<BR/>Randomised: 337<BR/>Evaluable: 119 (10 dropouts and 208 with unspecified eczema)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:00:14 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Hydrocortisone butyrate ointment and mupirocin ointment both applied o.d. versus hydrocortisone butyrate and vehicle ointment applied o.d. (with 2 to 3h between each application) for 28 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. EASI (Eczema Area and Severity Index) score at start and at 28 days.<BR/>2. Swabs from most severe lesion and non lesional skin.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Performed subgroup analysis at end of study which were not part of the pre-determined outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:28 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Harper-1995">
<CHAR_METHODS>
<P>D: cross over<BR/>AC: Not stated<BR/>RS: Computer generated random code<BR/>B: Unclear<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:28 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, Single centre, UK<BR/>Incl: atopic eczema, &gt; six months old<BR/>Excl: Systemic or topical antibiotics or systemic steroids within two weeks of study<BR/>Age: mean 4.5 (range 1 to 9)<BR/>Duration: Not stated<BR/>Randomised: 30<BR/>m/f: 9/17<BR/>Evaluable: 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:00:59 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Oilatum Plus vs Oilatum<BR/>15 ml in an 8 inch bath of water, soak for 10 to 15 min daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Global impression/change<BR/>2. Patients rating of skin<BR/>3. Adverse events<BR/>4. Total score in scale (Costa et al)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:37 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Hizawa-1998">
<CHAR_METHODS MODIFIED="2008-05-06 15:03:16 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: with-in patient study (L/R comparison)<BR/>AC: Not stated<BR/>RS: Drawing lots<BR/>B: Participant N, Clinician U, Outcome assessor Y<BR/>ITT+</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:37 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, Japan<BR/>Incl: mild to moderate atopic dermatitis with similar eczema in bilateral elbow fossae<BR/>Excl: Skin infection showing pus on exudate<BR/>Age: 12 to 29<BR/>Duration: Not stated<BR/>Randomised: 15<BR/>m/f: 3/12<BR/>Evaluable: 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:01:36 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Povidone iodine 10% vs unspecified placebo<BR/>Applied bd for one week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:03:49 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Visual analogue scale (VAS) of symptoms rated by dermatologists &amp; patients<BR/>2. Itch rated on VAS<BR/>3. Colony counts of <I>S aureus</I> from elbow lesions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Paper kindly reviewed by Dr Yukihiro Ohya</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:52 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Hjorth-1985">
<CHAR_METHODS MODIFIED="2008-05-06 15:04:11 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: with-in patient study (L/R comparison)<BR/>AC: Not stated<BR/>RS: Not stated<BR/>B: participant Y, clinician &amp; outcome assessor U<BR/>ITT +</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:52 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, three centres, Denmark<BR/>Incl: atopic dermatitis<BR/>Excl: &lt; two yrs old, pregnancy<BR/>No separate data on age/sex/duration for atopic dermatitis<BR/>Randomised: 60<BR/>Evaluable: 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:05:00 +0100" MODIFIED_BY="Diane A  Horsley">
<P>0.1% betamethasone 17-valerate plus 2% microcrystalline fusidic acid (Fucibet) vs 0.1% betamethasone 17-valerate (Betnovate)<BR/>Applied b.d. for seven days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:05:06 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Global degree of improvement<BR/>2. Adverse events<BR/>3. Sensitivity to fusidic acid<BR/>4. Isolation rate of <I>S Aureus</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results taken from a larger study of "symmetrical steroid responsive dermatoses"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:10:58 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Holland-1995">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated<BR/>RS: not stated<BR/>B: Unclear<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:10:58 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, UK.<BR/>Incl: moderate or severe atopic eczema with <I>S Aureus</I> present on skin<BR/>Excl: Use of bath emollients, antiseptic bath additives or medicated soaps in past 2 weeks. Systemic or topical antibacterials or oral steroids in last month.<BR/>Age: mean 17.3 (range 4 to 34)<BR/>Duration: not stated<BR/>Randomised: 15<BR/>m/f: 6/9<BR/>Evaluable: not clear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:05:47 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Oilatum Plus (containing triclosan &amp; benzalkonium chloride) vs Oilatum.<BR/>15ml in 8 inches of water from 10 to15 min soak daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. composite scale of Staughton et al.<BR/>2. William &amp; Kligman scrub method for non-lesional and lesional skin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:07:11 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Juenger-2006">
<CHAR_METHODS MODIFIED="2008-04-30 10:02:17 +0100" MODIFIED_BY="Finola M Delamere">
<P>D: parallel group<BR/>AC: Closed envelopes, but not stated to be sequentially numbered or opaque.<BR/>RS: Randomisation list by independent biometrician using statistics software.<BR/>B: participant Y, clinician N, outcome assessor N.<BR/>ITT: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:06:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Single centre, Germany.<BR/>Incl: "acute" atopic dermatitis, participants &gt; two yrs old.<BR/>Excl: Acute viral infection, acute "staphyloderma," other skin disease that could influence evaluation, u.v. treatment, topical or systemic immunosuppressive or immunomodulating treatment, topical or systemic antibiotics, severe generalised disease, pregnancy, female not on contraception, allergy to silver.<BR/>Age (median): Silver textile group 21, silver free textile group 25.5, steroid ointment 20.<BR/>Duration (yrs): silver textile 20.5, silver free textile 25.5, steroid oint 16.<BR/>Randomised: 30<BR/>m/f: silver textile 6/4, silver free textile 3/7, steroid oint 5/5.<BR/>Evaluable: 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:07:11 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Long-sleeved undershirt &amp; long underpants with silver thread versus identical garment with polyester thread versus prednicarbate 0.25% ointment all for 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Global rating of patient/carer "overall disease control" on scale from 0 (controlled) to 3 (not controlled).<BR/>2. Asked patients with regards adverse events.<BR/>3.SCORAD at day 14.<BR/>4. Skin lesional swabs - colony counts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Participants were allowed to use as much prednicarbate ointment as they wished; those in the silver textile group used almost as much as those in the prednicarbate group whereas those in the non-silver group barely used any.<BR/>Do not provide adequate data for primary outcomes for this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:12:20 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Korting-1994">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated<BR/>RS: not stated<BR/>B: participant Y, clincian U, outcome assessor U<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:12:04 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, six centres, Germany<BR/>Incl: atopic eczema suggestive of heavy <I>S aureus</I> colonisation with &gt; 10 to power 6 CFU/cm2<BR/>Excl: age &lt; 12 (though varied later), infection requiring antibiotics, other severe disease, pregnant, antibiotics last 48h<BR/>Age: not stated (&gt; 18 yrs)<BR/>Duration: not stated<BR/>Randomised: unclear 143 "recruited"<BR/>m/f: 54/89<BR/>Evaluable: unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednicarbate 0.25% cream plus didecyldimethyl - ammonium chloride 0.25% vs prednicarbate 0.25% cream applied b.d. for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:12:20 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Doctor's opinion of efficacy<BR/>2. Presence of <I>S aureus</I> at initially lesional site (William &amp; Kligman method)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:13:05 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Lever-1988">
<CHAR_METHODS>
<P>D: cross over<BR/>AC: not stated<BR/>RS: not stated<BR/>B: participant U, <BR/>clinician U, outcome assessor Y <BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:12:41 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, UK.<BR/>Incl: atopic dermatitis, participants &gt; two yrs old.<BR/>Excl: potent topical steroids, topical or systemic antibiotics during past 4 weeks.<BR/>Age: (mean) M/P 22.4 (2 - 52), P/M 20.4 (2 -56).<BR/>Duration: not stated<BR/>Randomised: 49<BR/>m/f: M/P 12/12, P/M 12/9<BR/>Evaluable: 45</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:13:05 +0100" MODIFIED_BY="Diane A  Horsley">
<P>2% mupirocin ointment followed by placebo (polyethylene glycol ointment) or vice-versa<BR/>Daily for two weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:13:01 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Emergence of resistant organisms<BR/>2. Adverse events<BR/>3. Isolation rates of <I>S Aureus</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Provides lots of data, but not corresponding to our outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:14:01 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Leyden-1977">
<CHAR_METHODS>
<P>D: parallel group AC: not stated<BR/>RS: not stated<BR/>B: Unclear<BR/>ITT not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:13:23 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, USA.<BR/>Incl: unclear. Not used antibacterial soaps or antibiotic therapy for previous month.<BR/>Excl: None stated<BR/>Age: not stated<BR/>Duration: not stated<BR/>Randomised: 36<BR/>m/f: not stated<BR/>Evaluable: 36</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:13:42 +0100" MODIFIED_BY="Diane A  Horsley">
<P>fluocinolone acetonide plus 0.5% neomycin sulphate (Neo-synelar) cream vs fluocinolone acetonide (Synelar) cream applied bd for one week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:14:01 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Pruritus score (0 to 3)<BR/>2. Improvement in erythema, lichenification, oozing and crusting, scaling (scored 0-3, then graded % reduction - unclear to what this refers)<BR/>3. Change in isolation rate of <I>S aureus</I>
<BR/>4. Change in bacterial counts of <I>S aureus</I>.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Two studies were reported in this paper. Only study I was included as study II did not have proper controls.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:15:28 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Masako-2005b">
<CHAR_METHODS MODIFIED="2008-05-06 15:15:16 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: with-in patient study (R/L comparison)<BR/>AC: unclear<BR/>RS: Unclear<BR/>B: participant Y, clinician U, outcome assessor Y<BR/>ITT: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single centre, Japan.<BR/>Incl: mild - moderate atopic dermatitis, (n=17) mean age 29.8 yrs.<BR/>Exclusion criteria: None stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-29 14:18:53 +0100" MODIFIED_BY="Diane A  Horsley">
<P>FX cream: 0.2% Farnesol + 5% xylitol cream versus placebo cream (identical in appearance) for 7 days to L or R arms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Scores of dryness and scaling.<BR/>2. Change in CFU of SA using stamp bottle method</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-06 15:15:28 +0100" MODIFIED_BY="Diane A  Horsley">
<P>There were no loss to follow-up or adverse events.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:17:37 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Nilsson-1992">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated<BR/>RS: not stated<BR/>B: Unclear<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:15:41 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, Sweden.<BR/>Incl: moderate - severe atopic dermatitis (Hanifin &amp; Rajka criteria)<BR/>Excl: skin infection requiring oral antibiotics.<BR/>Age: unclear<BR/>Duration: not stated<BR/>Randomised: 30<BR/>m/f: not stated<BR/>Evaluable: 28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:16:17 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Betamethasone plus neomycin cream vs clobetasol cream<BR/>applied to all affected areas except face bd for one week, then od for one1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:17:37 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Patient global scale (up to eight)<BR/>2. Changes in individual signs of one area (graded 0 to 3)<BR/>3. Isolation of <I>S aureus</I> from most severe lesion<BR/>4. Density of <I>S aureus</I> from most severe lesion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:18:22 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Polano-1960">
<CHAR_METHODS MODIFIED="2008-05-06 15:17:42 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: crossover with four periods<BR/>AC: identical tubes pre-prepared by pharmacy<BR/>RS: unclear (selection of a card)<BR/>B: participant U, clinician Y, outcome assessor Y<BR/>ITT-</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:18:00 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, The Netherlands.<BR/>Incl: neurodermatitis without apparent secondary infection, having failed to react to standard treatment of outpatient department.<BR/>Excl: none stated<BR/>Age: not stated<BR/>Duration: 'longstanding'<BR/>Randomised: 24<BR/>m/f: not stated<BR/>Evaluable: 14</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:18:18 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Metiderm (0.5% prednisolone plus 0.5% neomycin) vs 0.5% prednisolone vs 1% hydrocortisone vs petrolatum base (used in all other ointments). Applied for one week. Frequency not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:18:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Score (0 to 5) for lichenification, redness, weeping, crusting, apparent secondary infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-29 14:20:15 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Outcomes were pooled without giving primary data, thus not fulfilling outcome measures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:19:11 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Ramsay-1996">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated<BR/>RS: not stated<BR/>B: unclear<BR/>ITT-</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:18:57 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, number of centres unclear, Canada<BR/>Incl: mild - moderate atopic dermatitis, amenable to treatment with topical steroid, age &gt; three years<BR/>Excl: Systemic steroids or antibiotics, topical antibiotics or "other effective topical therapy" (past seven days)<BR/>Age: not stated<BR/>Duration: not stated<BR/>Randomised: 186<BR/>m/f: not stated<BR/>Evaluable: 154</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fucidic acid 2% plus 1% hydrocortisone cream (FH) vs 1% hydrocortisone cream (H) for 2 weeks. <BR/>Frequncy not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:19:05 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Patient severity score (0 to 3)<BR/>2. Investigator global response<BR/>3. Adverse events<BR/>4. Absent (0), mild (1), moderate (2), severe (3) for each of erythema, scaling, oedema, discharge, crusting<BR/>5. Lesional swabs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-06 15:19:11 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Reported two studies. Study II (comparing topical 2% fusidic acid) excluded as pooled data from study I. Unclear if pathogens were S aureus</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:20:29 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Schempp-2003">
<CHAR_METHODS MODIFIED="2008-05-06 15:19:47 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: with-in patient study (left/right comparison)<BR/>AC: not stated<BR/>RS: not stated<BR/>B: participant Y, clinician Unclear (U), outcome assessor U<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:20:18 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, Germany<BR/>Incl: subacute atopic dermatitis with SCORAD &lt;80<BR/>Excl: Infectious disease, severe underlying clinical disease, cancer, poor health, dependence on alcohol/drugs, pregnancy, breast feeding, other study &lt; four weeks ago, use of oral steroids &lt; two 2 weeks ago or topically &lt; one week ago, current treatment with psychotropic, anti-inflammatory, antibiotic, immunomodulatory drugs.<BR/>Age: 30.4 +/- 12.9<BR/>Duration: not stated<BR/>Randomised: 21<BR/>m/f: 10/8<BR/>Evaluable: 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:20:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Hyperforin 1.5% vs placebo cream<BR/>Applied b.d. for four weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:20:29 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. modified SCORAD<BR/>2. effect on bacterial colonisation with <I>S aureus</I> (no. of colony forming units)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Cream was manufactured to GMP standards</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:25:54 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Schuttelaar-2005">
<CHAR_METHODS MODIFIED="2008-05-06 15:25:05 +0100" MODIFIED_BY="Diane A  Horsley">
<P>D: parallel group<BR/>AC: Concealed packs in pharmacy<BR/>RS: Computer generated in blocks of four<BR/>B: participant Y, clinician Y, outcome assessor Y<BR/>ITT +</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:25:34 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, The Netherlands.<BR/>Incl: Atopic eczema (modified Hanifin &amp; Rajka criteria, SCORAD &gt;35), &gt;18 years old<BR/>Excl: investigational drugs, NSAIDs, light therapy, systemic steroids or topical/systemic antibiotics past four weeks, topical steroids &gt;class I or tar past seven days, known hypersensitivity to drug, pregnant, breast feeding.<BR/>Age: TT 36.8, T 31.1, overall mean 33.9<BR/>Duration: not stated<BR/>Randomised: 44<BR/>m/f: TT 8/14, T 5/17<BR/>Evaluable: 44</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:25:42 +0100" MODIFIED_BY="Diane A  Horsley">
<P>TT: 3% tetracycline + 0.1% triamcinolone acetonide in oculentum simplex FNA<BR/>T: 0.1% triamcinolone in oculentum simplex FNA<BR/>Applied all over body b.d. for two weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:25:54 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Severe and minor adverse effects<BR/>2. Global change in SCORAD and SASSAD<BR/>3.Isolation rates of <I>S aureus</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:28:58 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Wachs-1976">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC: not stated <BR/>RS: not stated<BR/>B: participant U, clinician U, outcome assessor U<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:26:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, single centre, USA.<BR/>Incl: clinically infected, moderate to severe atopic dermatitis<BR/>Excl: Pregnant, age &lt; one year, renal disease, symptoms requiring oral antibiotics or steroids<BR/>Age: not stated<BR/>Duration: not stated<BR/>Randomised: 83<BR/>m/f: not stated<BR/>Evaluable: 79</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 15:28:58 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Betamethasone valerate (Betnovate) plus gentamicin cream (BV/G) vs betmethasone valerate cream (BV) vs gentamicin cream (G)<BR/>Applied three times daily for 22 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Physician graded global assessment <BR/>2. Erythema, pustules, crusting, exudate, vesiculation, lichenification<BR/>3. Swabs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 15:27:39 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Weinberg-1992">
<CHAR_METHODS>
<P>D: parallel group<BR/>AC:not stated<BR/>RS: not stated<BR/>B: participant U, clinicain U, outcome assessor U<BR/>ITT -</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 15:27:17 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two-care, South Africa.<BR/>Incl: <I>S aureus</I> super-infected atopic dermatitis (Hanifin &amp; Rajka criteria)<BR/>Excl: Cefadroxil resistant organisms, 'concomitant medications that could have affected the variables being measured.'<BR/>Age: Cef: 4.1, P 4.4<BR/>Duration (yrs): Cef: 3.2, P 2.6<BR/>Randomised: 33 (Cef: 16, P: 17)<BR/>m/f: Cef: 7/6, P: 7/10<BR/>Evaluable: Cef: 13, P: 17</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cefadroxil 50mg/kg/day in 2 equal doses vs placebo for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-06 15:27:39 +0100" MODIFIED_BY="Diane A  Horsley">
<P>1. Patient and physician rated global evaluations<BR/>2. Adverse events<BR/>3. Pruritus<BR/>4. Skin swab sensitivity from three sites<BR/>5. Changes in erythema and peeling<BR/>6. Isolation of <I>S aureus</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>D: design<BR/>AC: method of allocation concealment<BR/>RS: method of generating randomisation sequence<BR/>B: blinding (participant, clinician, outcome assessor)<BR/>ITT: per protocol<BR/>PP: per protocol<BR/>two-care: secondary healthcare setting<BR/>Incl: inclusion criteria<BR/>Excl: exclusion criteria<BR/>m/f: male to female ratio<BR/>od: once daily<BR/>b.d.: twice daily<BR/>qds: four times a day</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-05-06 15:33:50 +0100" MODIFIED_BY="Diane A  Horsley" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bjornberg-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study not randomised or controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breneman-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No separate results for atopic eczema.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carpenter-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies "common dermatoses." No separate results for atopic eczema.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clark-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not specifically atopic dermatitis and not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not specifically study atopic dermatitis, rather 'inflammatory and infective dermatoses.'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eaglstein-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studied secondarily infected "dermatitis" with no description of atopic dermatitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gauger-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label, controlled R/L comparison. Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:29:38 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-GP-medical-research">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:29:38 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared anti-staphylococcal - steroid combination with addition of antifungal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kimata-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lloyd-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not specify results for atopic dermatitis from amongst other dermatoses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masako-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Was an in vitro study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:31:22 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Meenan-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:31:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two anti-staphylococcal - steroid combinations. i.e. comparator was not without an antibacterial agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Remitz-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control, and not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:31:27 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Rist-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:31:27 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two anti-staphylococcal agents. i.e. comparator was not without an antibacterial agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:31:35 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Salo-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:31:35 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two preparations of the same anti-staphylococcal agent. i.e. no appropriate control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sasai_x002d_Takedatsu-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo controlled clinical trial. Treatment arbitrarily divided by a referee physician. i.e. not appropriately randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schempp-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Same study as Schempp 2003 which is published in German in this case.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:31:57 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Stalder-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:31:57 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two anti-staphylococcal agents. i.e. comparator was not without an antibacterial agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:32:39 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Thaci-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:32:39 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two formulations of topical steroid and antibiotic plus vehicle control. Excluded as it cannot be determined whether the antibiotic has any effect - it is well known that a topical steroid will be better than placebo at controlling disease and reducing bacterial counts and thus it cannot be determined if the addition of antibiotic has any additional benefit.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theodoridis-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studied "eczematous dermatitis" without any further description of atopic dermatitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:33:28 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Weitgasser-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:33:28 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared two different anti-staphylococcal - steroid combinations in a variety of dermatoses with no separate atopic eczema results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whitefield-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised or controlled in vitro study and case series using antimicrobial lotion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilkinson-JD-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared two different steroid - antibiotic combinations in a mixture of eczemas with no separate results for atopic eczema.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-06 15:33:50 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Wilkinson-RD-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-06 15:33:50 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Compared three steroid - antibiotic combinations. i.e. comparator was not without an antibacterial agent. No separate results for atopic eczema.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zienicke-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate of Korting 1994.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-03-28 16:40:06 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Gauger-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Huang-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Senti-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boguniewicz-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Breneman-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ewing-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fattah-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gong-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Harper-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hizawa-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hjorth-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Holland-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Juenger-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Korting-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lever-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leyden-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Masako-2005b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nilsson-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Polano-1960">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ramsay-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schempp-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schuttelaar-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wachs-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Weinberg-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-06 15:38:22 +0100" MODIFIED_BY="Diane A  Horsley">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-06 15:38:22 +0100" MODIFIED_BY="Diane A  Horsley" NO="1">
<TITLE>Quality of studies</TITLE>
<TABLE COLS="10" ROWS="22">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Allocat'n generation</P>
</TH>
<TH>
<P>Allocat'n concealmen</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>Loss to follow up</P>
</TH>
<TH>
<P>Included in analysis</P>
</TH>
<TH>
<P>Diagnostic certainty</P>
</TH>
<TH>
<P>Baseline severity</P>
</TH>
<TH>
<P>Baseline S. aureus</P>
</TH>
<TH>
<P>Amount of steroid</P>
</TH>
</TR>
<TR>
<TD>
<P>Boguniewicz 2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant blinded. Clinician and outcome assessor unclear</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Unclear. Atopic dermatitis who had S. aureus cultured from their skin</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Breneman 2000</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant blinded. Clinician and outcome assessor unsure</P>
</TD>
<TD>
<P>Unsure</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Hanifin &amp; Rajka</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>No statistical difference between groups (p=0.86)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ewing 1998</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Adequate - by pharmaceutical company</P>
</TD>
<TD>
<P>Participant blinded. Clinician and outcome assessor unclear</P>
</TD>
<TD>
<P>Four</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Hanifin &amp; Rajka</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Flucloxacillin group used mean of 61.0g, placebo group used 29.2g.</P>
</TD>
</TR>
<TR>
<TD>
<P>Fattah 1976</P>
</TD>
<TD>
<P>Unclear, though stated "a code of randomisation"</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participants not blinded as creams different colours. Clinician and outcome assessor unclear</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Gong 2006</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>All blinded. Clinician nd outcome assessor unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Per protocol (though in text states was ITT)</P>
</TD>
<TD>
<P>Hanifin &amp; Rajka criteria</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Harper 1995</P>
</TD>
<TD>
<P>Computer generated random code</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Four</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>"Total clinical score" of control 6.4 +/- 3.8 and intervention 9.6 +/- 2.6</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Hizawa 1998</P>
</TD>
<TD>
<P>By lots</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant and clinician unclear. Outcome assessor blinded</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Unclear. "Atopic dermatitis"</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No steroid permitted during trial</P>
</TD>
</TR>
<TR>
<TD>
<P>Hjorth 1985</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant blinded. Clinician and outcome assessor unclear.</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Holland 1995</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Five</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Juenger 2006</P>
</TD>
<TD>
<P>"Randomisation list" by independent biometrician using SPSS</P>
</TD>
<TD>
<P>Unclear; hidden in closed envelope, but not stated to be opaque</P>
</TD>
<TD>
<P>Participant blinded. Clinician nd outcome assessor unclear</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Unclear; "acute" atopic dermatitis</P>
</TD>
<TD>
<P>Unequal. SCORAD in silver group 74.6, SCORAD in non-silver group 51.9</P>
</TD>
<TD>
<P>Unequal. Silver group 31 +/- 0.7, Non-silver group 1.8 +/- 1.1</P>
</TD>
<TD>
<P>Very unequal. Silver group used 135g prednicarbate ointment per person, non-silver group used 13 g per person</P>
</TD>
</TR>
<TR>
<TD>
<P>Korting 1994</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant blinded. Clinician and outcome assessor unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Lever 1988</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear for participant and clinician. Outcome assessor blinded</P>
</TD>
<TD>
<P>Four</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear. "Typical clinical features"</P>
</TD>
<TD>
<P>"Pre-treatment severity scores" Mupirocin first: 59.5 +/- 6.4; Placebo first 69.9 +/- 6.9</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Leyden 1977</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear for all</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear. "Typical atopic dermatitis"</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>S. aureus counts: Treatment group - 420000/cm2; Control group - 200000/cm2</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Masako 2005</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant and outcome assessor blinded. Clinician unclear.</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Unclear; atopic dermatitis</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Nilsson 1992</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Two</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Hanifin &amp; Rajka criteria</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Polano 1960</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Adequate - states card was chosen at random through the pharmacy</P>
</TD>
<TD>
<P>Participant - unclear, Clinician and outcome assessor blinded</P>
</TD>
<TD>
<P>Ten. Reasons not specified</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Ramsay 1996</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>At least 12 (unclear)</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear, atopic dermatitis</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Schempp 2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Participant blinded, clinician and outcome assessor unclear</P>
</TD>
<TD>
<P>None, though three excluded post randomisation</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear. "sub acute atopic dermatitis"</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>None permitted</P>
</TD>
</TR>
<TR>
<TD>
<P>Schuttelaar 2005</P>
</TD>
<TD>
<P>Computer generation in blocks of four</P>
</TD>
<TD>
<P>Adequate - by pharmacy using concealed packs</P>
</TD>
<TD>
<P>All blinded</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Modified Hanifin &amp; Rajka criteria</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>462g in 2 weeks (Intervention group), 349g in 2 weeks (Control)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wachs 1976</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear, though states was double blind</P>
</TD>
<TD>
<P>Four participants - no reason specified</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Unclear; "infected atopic dermatitis"</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>
<I>S.aureus</I> not specifically reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Weinberg 1992</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Three</P>
</TD>
<TD>
<P>Per protocol</P>
</TD>
<TD>
<P>Hanifin &amp; Rajka</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Similar</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-06 16:08:49 +0100" MODIFIED_BY="Diane A  Horsley">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-06 16:01:25 +0100" MODIFIED_BY="Diane A  Horsley" NO="1">
<NAME>Oral Antibiotics vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-04-02 16:06:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="38" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Global outcome (not good or excellent)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.892152666699612" CI_START="1.2709281694092356" EFFECT_SIZE="2.4935064935064934" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.6895000013631586" LOG_CI_START="0.10412100569897681" LOG_EFFECT_SIZE="0.3968105035310677" ORDER="324" O_E="0.0" SE="0.343854519725902" STUDY_ID="STD-Ewing-1998" TOTAL_1="22" TOTAL_2="24" VAR="0.11823593073593072" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2430951431299282" CI_START="0.12770739414726937" EFFECT_SIZE="0.3984375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.0945043696352191" LOG_CI_START="-0.8937839567350832" LOG_EFFECT_SIZE="-0.399639793549932" ORDER="325" O_E="0.0" SE="0.5805254550160299" STUDY_ID="STD-Weinberg-1992" TOTAL_1="16" TOTAL_2="17" VAR="0.3370098039215686" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30023491959327964" CI_END="12.77912061577535" CI_START="0.21109570924379206" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.642442549953898" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.106500969248328" LOG_CI_START="-0.6755205941233362" LOG_EFFECT_SIZE="0.21549018756249594" METHOD="MH" NO="2" P_CHI2="0.5837352751515617" P_Q="0.0" P_Z="0.6354887873707529" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="42" WEIGHT="100.0" Z="0.4740155959113788">
<NAME>Adverse events requiring withdrawal from treatment</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="326" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Ewing-1998" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="57.068950398971154"/>
<DICH_DATA CI_END="72.7468601168141" CI_START="0.13869966871039935" EFFECT_SIZE="3.176470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8618142531442754" LOG_CI_START="-0.857924576254886" LOG_EFFECT_SIZE="0.5019448384446945" ORDER="327" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Weinberg-1992" TOTAL_1="16" TOTAL_2="17" VAR="2.5522875816993467" WEIGHT="42.931049601028846"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.510602539448496E-32" CI_END="0.8264005277457847" CI_START="-0.02640052774578422" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4000000000000002" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-05-06 15:59:27 +0100" MODIFIED_BY="Diane A  Horsley" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.06597211390487928" Q="0.0" RANDOM="YES" SCALE="1.326392754877722" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.8386130945021395">
<NAME>Mean erythema scores as assessed by a physician at end of treatment</NAME>
<GROUP_LABEL_1>Flucloxacillin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flucloxacill</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8264005277457845" CI_START="-0.026400527745784275" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.7" ORDER="328" SD_1="0.83" SD_2="0.62" SE="0.21755528729567347" STUDY_ID="STD-Ewing-1998" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-05-06 15:56:48 +0100" MODIFIED_BY="Diane A  Horsley" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.3409500025233398" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean erythema scores as assessed by physician 56 days post treatment</NAME>
<GROUP_LABEL_1>Flucloxacillin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours flucloxacill</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3939476731987396" CI_START="-0.5939476731987398" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.0" MODIFIED="2008-04-02 16:15:29 +0100" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="0.88" SD_2="0.64" SE="0.2520187498826182" STUDY_ID="STD-Ewing-1998" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 16:00:09 +0100" MODIFIED_BY="Diane A  Horsley" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.31949566069344" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number of people with erythema at end of treatment</NAME>
<GROUP_LABEL_1>Cefadroxil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cefadroxil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.279052013696273" CI_START="0.3828254747759961" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3577542369853343" LOG_CI_START="-0.4169991701989361" LOG_EFFECT_SIZE="-0.029622466606800863" ORDER="330" O_E="0.0" SE="0.4550939864712576" STUDY_ID="STD-Weinberg-1992" TOTAL_1="13" TOTAL_2="17" VAR="0.20711053652230121" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Presence of clinically apparent infection at the end of study</NAME>
<GROUP_LABEL_1>Cefadroxil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cefadroxil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9426734158536222" CI_START="0.003838092455836316" EFFECT_SIZE="0.06015037593984962" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.025638740198592174" LOG_CI_START="-2.4158845677516925" LOG_EFFECT_SIZE="-1.2207616539751422" ORDER="331" O_E="0.0" SE="1.40404223101236" STUDY_ID="STD-Weinberg-1992" TOTAL_1="13" TOTAL_2="15" VAR="1.971334586466165" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 16:00:54 +0100" MODIFIED_BY="Diane A  Horsley" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.769753342075294" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients in whom <I>S aureus</I> was isolated at end of study</NAME>
<GROUP_LABEL_1>Flucloxacillin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Flucloxacill</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9508059012297396" CI_START="0.4889284263555753" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="-0.02190813146262149" LOG_CI_START="-0.31075471207042854" LOG_EFFECT_SIZE="-0.16633142176652504" ORDER="332" O_E="0.0" SE="0.16966991126265965" STUDY_ID="STD-Ewing-1998" TOTAL_1="24" TOTAL_2="24" VAR="0.0287878787878788" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-05-06 16:01:25 +0100" MODIFIED_BY="Diane A  Horsley" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.255407750888907" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="21" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean log of <I>S aureus</I> counts from lesional skin</NAME>
<GROUP_LABEL_1>Flucloxacillin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours flucloxacill</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.290014978637825" CI_START="-3.090014978637825" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.0" ORDER="333" SD_1="3.27" SD_2="2.11" SE="0.8622683845052498" STUDY_ID="STD-Ewing-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-05-06 16:02:25 +0100" MODIFIED_BY="Diane A  Horsley" NO="2">
<NAME>Topical antibiotic vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 16:02:25 +0100" MODIFIED_BY="Diane A  Horsley" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients in whom <I>S aureus</I> was isolated at end of study</NAME>
<GROUP_LABEL_1>Topical mupirocin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placbeo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4359606704407551" CI_START="0.00896009724008084" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3605526882107347" LOG_CI_START="-2.0476872771011143" LOG_EFFECT_SIZE="-1.2041199826559248" ORDER="334" O_E="0.0" SE="0.9910312089651148" STUDY_ID="STD-Lever-1988" TOTAL_1="24" TOTAL_2="21" VAR="0.982142857142857" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-06 16:07:56 +0100" MODIFIED_BY="Diane A  Horsley" NO="3">
<NAME>Topical steroid plus antibiotic vs topical steroid</NAME>
<DICH_OUTCOME CHI2="0.674438821944588" CI_END="1.1550133743174948" CI_START="0.23179464872040187" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5174223800409968" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.06258701311011841" LOG_CI_START="-0.6348965945071382" LOG_EFFECT_SIZE="-0.28615479069850985" METHOD="MH" MODIFIED="2008-05-06 16:03:41 +0100" MODIFIED_BY="Diane A  Horsley" NO="1" P_CHI2="0.41150863995327824" P_Q="0.0" P_Z="0.10778729314763381" Q="0.0" RANDOM="YES" SCALE="36.97180290931262" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="101" WEIGHT="100.0" Z="1.6082186811204437">
<NAME>Global outcome (Not good or excellent)</NAME>
<GROUP_LABEL_1>Steroid + antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6763718425004068" CI_START="0.24700025478483284" EFFECT_SIZE="0.6434782608695652" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.22437035751291787" LOG_CI_START="-0.6073025987581889" LOG_EFFECT_SIZE="-0.19146612062263552" ORDER="335" O_E="0.0" SE="0.48852881136117726" STUDY_ID="STD-Korting-1994" TOTAL_1="69" TOTAL_2="74" VAR="0.23866039952996473" WEIGHT="70.33360063509414"/>
<DICH_DATA CI_END="1.3478394059073329" CI_START="0.07064367321009946" EFFECT_SIZE="0.30857142857142855" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12963814940764862" LOG_CI_START="-1.1509267271343007" LOG_EFFECT_SIZE="-0.510644288863326" ORDER="336" O_E="0.0" SE="0.7522101473791123" STUDY_ID="STD-Wachs-1976" TOTAL_1="25" TOTAL_2="27" VAR="0.5658201058201058" WEIGHT="29.666399364905857"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-05-06 16:04:15 +0100" MODIFIED_BY="Diane A  Horsley" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.5088036692514395" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="13" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Global outcome (Not good or excellent)</NAME>
<GROUP_LABEL_1>Betamethasone+neomyc</GROUP_LABEL_1>
<GROUP_LABEL_2>Clobetasol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth+neo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clobetasol</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1460239987852376" CI_START="0.2539760012147624" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="0.5" ORDER="337" SD_1="1.6" SD_2="0.9" SE="0.4826741747539006" STUDY_ID="STD-Nilsson-1992" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.44285462592378966" CI_END="2.7776986338903513" CI_START="0.087711066835647" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49359387205114486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.44368512522514214" LOG_CI_START="-1.056945606606268" LOG_EFFECT_SIZE="-0.3066302406905629" METHOD="MH" MODIFIED="2008-05-06 16:04:50 +0100" MODIFIED_BY="Diane A  Horsley" NO="3" P_CHI2="0.5057478817962844" P_Q="0.0" P_Z="0.4231458344772083" Q="0.0" RANDOM="YES" SCALE="33.264996162283424" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="105" WEIGHT="100.00000000000001" Z="0.8009755039347944">
<NAME>Adverse events requiring withdrawl of treatment</NAME>
<GROUP_LABEL_1>Seroid+antib/antibio</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid+anti</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.865960832196956" CI_START="0.03225229621777004" EFFECT_SIZE="0.304029304029304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4572702507937171" LOG_CI_START="-1.4914393601230815" LOG_EFFECT_SIZE="-0.5170845546646822" ORDER="338" O_E="0.0" SE="1.1446816717206745" STUDY_ID="STD-Ramsay-1996" TOTAL_1="91" TOTAL_2="83" VAR="1.310296129573238" WEIGHT="59.2998259036002"/>
<DICH_DATA CI_END="15.000438199046616" CI_START="0.06666471917224105" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1761039460322296" LOG_CI_START="-1.1761039460322296" LOG_EFFECT_SIZE="0.0" ORDER="339" O_E="0.0" SE="1.381698559415515" STUDY_ID="STD-Schuttelaar-2005" TOTAL_1="22" TOTAL_2="22" VAR="1.9090909090909092" WEIGHT="40.70017409639981"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5504190792093799" CI_END="0.7747766354671972" CI_START="0.14722583356804153" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33773826550407454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.11082348454645695" LOG_CI_START="-0.8320159780986256" LOG_EFFECT_SIZE="-0.4714197313225413" METHOD="MH" MODIFIED="2008-05-06 16:05:43 +0100" MODIFIED_BY="Diane A  Horsley" NO="4" P_CHI2="0.4581466051658718" P_Q="0.0" P_Z="0.010397321025406877" Q="0.0" RANDOM="YES" SCALE="10.523427827592673" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="105" WEIGHT="99.99999999999999" Z="2.5623275429360612">
<NAME>Minor adverse events not requiring withdrawl from treatment</NAME>
<GROUP_LABEL_1>Steroid+antibac/anti</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid+anti</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5494973292563983" CI_START="0.10416553008412306" EFFECT_SIZE="0.608058608058608" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5501668537346772" LOG_CI_START="-0.9822759717360793" LOG_EFFECT_SIZE="-0.21605455900070097" ORDER="340" O_E="0.0" SE="0.9001645013958492" STUDY_ID="STD-Ramsay-1996" TOTAL_1="91" TOTAL_2="83" VAR="0.8102961295732379" WEIGHT="22.147965334507735"/>
<DICH_DATA CI_END="0.7321745386817131" CI_START="0.11149343325732798" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.13538537775208032" LOG_CI_START="-0.952750710948471" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="341" O_E="0.0" SE="0.48012444274321264" STUDY_ID="STD-Schuttelaar-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.23051948051948046" WEIGHT="77.85203466549225"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2008-05-06 16:06:04 +0100" MODIFIED_BY="Diane A  Horsley" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.874283346710302" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SCORAD at end of treatment</NAME>
<GROUP_LABEL_1>Steroid+antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid+anti</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.589875270810035" CI_START="-10.389875270810032" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="22.0" ORDER="342" SD_1="17.3" SD_2="16.5" SE="5.0969687961661005" STUDY_ID="STD-Schuttelaar-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2008-05-06 16:06:23 +0100" MODIFIED_BY="Diane A  Horsley" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.214011284936027" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="61" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean EASI score at end of treatment</NAME>
<GROUP_LABEL_1>HC+mupirocin</GROUP_LABEL_1>
<GROUP_LABEL_2>HC+ vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursHC+mupirocin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HC+vehicle</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.35047217787750484" CI_START="-2.5104721778775057" EFFECT_SIZE="-1.0800000000000003" ESTIMABLE="YES" MEAN_1="1.41" MEAN_2="2.49" ORDER="343" SD_1="2.32" SD_2="5.18" SE="0.7298461549094203" STUDY_ID="STD-Gong-2006" TOTAL_1="58" TOTAL_2="61" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.10629418833008915" CI_END="0.6852876423824318" CI_START="0.20322626969528634" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3731868851254811" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.16412709963380703" LOG_CI_START="-0.6920201544279612" LOG_EFFECT_SIZE="-0.42807362703088414" METHOD="MH" MODIFIED="2008-05-06 16:07:56 +0100" MODIFIED_BY="Diane A  Horsley" NO="7" P_CHI2="0.7444032836850725" P_Q="0.0" P_Z="0.0014793312595462833" Q="0.0" RANDOM="YES" SCALE="9.989497613070988" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="43" WEIGHT="99.99999999999999" Z="3.178707823838018">
<NAME>No of patients in whom <I>S aureus</I> was isotated at end of study</NAME>
<GROUP_LABEL_1>Steroid+antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid+anti</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9383972390912495" CI_START="0.11123082408675156" EFFECT_SIZE="0.3230769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.02761327865169093" LOG_CI_START="-0.9537748451661815" LOG_EFFECT_SIZE="-0.4906940619089363" ORDER="344" O_E="0.0" SE="0.5440318887443051" STUDY_ID="STD-Leyden-1977" TOTAL_1="15" TOTAL_2="21" VAR="0.295970695970696" WEIGHT="32.48765666540068"/>
<DICH_DATA CI_END="0.8381005075563139" CI_START="0.19090789059001878" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.07670389633430676" LOG_CI_START="-0.7191761210097685" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="345" O_E="0.0" SE="0.3773913650631694" STUDY_ID="STD-Schuttelaar-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.1424242424242424" WEIGHT="67.51234333459931"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-05-06 16:08:49 +0100" MODIFIED_BY="Diane A  Horsley" NO="4">
<NAME>Silver textile garment vs non-silver textile garment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 16:08:31 +0100" MODIFIED_BY="Diane A  Horsley" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="12.146285609113841" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients in complete remission or well under control at end of study</NAME>
<GROUP_LABEL_1>Silver Textile</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours silver texti</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.221122358714915" CI_START="0.984765353342748" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.8586047039843729" LOG_CI_START="-0.0066672394398107175" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="346" O_E="0.0" SE="0.5082650227325635" STUDY_ID="STD-Juenger-2006" TOTAL_1="10" TOTAL_2="10" VAR="0.2583333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2008-05-06 16:08:49 +0100" MODIFIED_BY="Diane A  Horsley" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.415839254442743" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean log of <I>S aureus</I> counts from lesional skin</NAME>
<GROUP_LABEL_1>Silver textiles</GROUP_LABEL_1>
<GROUP_LABEL_2>Non silver textiles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver text</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non silver t</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9296925484568425" CI_START="-0.9296925484568425" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.1" ORDER="347" SD_1="0.9" SD_2="1.2" SE="0.4743416490252569" STUDY_ID="STD-Juenger-2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-03-18 15:50:59 +0000" MODIFIED_BY="Finola M Delamere">
<APPENDIX ID="APP-01" MODIFIED="2008-03-18 15:50:59 +0000" MODIFIED_BY="Finola M Delamere" NO="1">
<TITLE MODIFIED="2008-03-18 15:50:59 +0000" MODIFIED_BY="Finola M Delamere">Cochrane Central Register of Controlled Trials Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-18 14:59:26 +0000" MODIFIED_BY="Diane A  Horsley">
<P>#1(atopic eczema):ti,ab,kw or (atopic dermatitis):ti,ab,kw or (neurodermatitis):ti,ab,kw or (besniers prurigo):ti,ab,kw or (infant* or child*) and eczema:ti,ab,kw<BR/>#2MeSH descriptor Dermatitis, Atopic explode all trees<BR/>#3MeSH descriptor Eczema explode all trees<BR/>#4MeSH descriptor Neurodermatitis explode all trees<BR/>#5(#1 OR #2 OR #3 OR #4)<BR/>#6(staphylococcus aureus):ti,ab,kw or (staphylococc*):ti,ab,kw or (S. and Aureus):ti,ab,kw<BR/>#7MeSH descriptor Staphylococcus aureus explode all trees<BR/>#8(#6 OR #7)<BR/>#9(antibiotic* or antiseptic* or anti-infective*):ti,ab,kw or (dermol or oilatum or emulsiderm or fusidic or fucidic or fucibet):ti,ab,kw or (gregoderm or nystaform or quinacort or terra-cortril):ti,ab,kw or (timodine or viofrom or locoid or betnovate or dermovate or trimovate):ti,ab,kw or (synalar or aureocort or triadcortyl or bactroban or flucloxacillin or erythromycin or clindamycin):ti,ab,kw<BR/>#10MeSH descriptor Anti-Infective Agents, Local explode all trees<BR/>#11MeSH descriptor Fusidic Acid explode all trees<BR/>#12MeSH descriptor Clioquinol explode all trees<BR/>#13MeSH descriptor Betamethasone 17-Valerate explode all trees<BR/>#14MeSH descriptor Fluocinolone Acetonide explode all trees<BR/>#15MeSH descriptor Mupirocin explode all trees<BR/>#16MeSH descriptor Floxacillin explode all trees<BR/>#17MeSH descriptor Erythromycin explode all trees<BR/>#18MeSH descriptor Clindamycin explode all trees<BR/>#19(clioquinol):ti,ab,kw<BR/>#20(betamethasone):ti,ab,kw<BR/>#21(flucinolone):ti,ab,kw<BR/>#22(mupirocin):ti,ab,kw<BR/>#23(floxacillin):ti,ab,kw<BR/>#24(#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23)<BR/>#25(#5 AND #8 AND #24)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-03-18 15:50:32 +0000" MODIFIED_BY="Finola M Delamere" NO="2">
<TITLE MODIFIED="2008-03-18 15:50:32 +0000" MODIFIED_BY="Finola M Delamere">MEDLINE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-18 15:50:00 +0000" MODIFIED_BY="Finola M Delamere">
<P>1. RANDOMIZED CONTROLLED TRIAL.pt.<BR/>2. CONTROLLED CLINICAL TRIAL.pt.<BR/>3. RANDOMIZED CONTROLLED TRIALS.mp.<BR/>4. RANDOM ALLOCATION.sh.<BR/>5. DOUBLE BLIND METHOD.sh.<BR/>6. SINGLE-BLIND METHOD.sh.<BR/>7. or/1-6<BR/>8. animal/ not human/<BR/>9. 7 not 8<BR/>10. CLINICAL TRIAL.pt.<BR/>11. CLINICAL TRIALS.mp.<BR/>12. (clin$ adj25 trial$).ti,ab.<BR/>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14. PLACEBOS.sh.<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. RESEARCH DESIGN.sh.<BR/>18. or/10-17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. COMPARATIVE STUDY.sh.<BR/>22. EVALUATION STUDIES.mp.<BR/>23. FOLLOW UP STUDIES.sh.<BR/>24. PROSPECTIVE STUDIES.sh.<BR/>25. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26. or/21-25<BR/>27. 26 not 8<BR/>28. 27 not (9 or 20)<BR/>29. 9 or 20 or 28<BR/>30. exp Dermatitis, Atopic/<BR/>31. atopic dermatitis.mp.<BR/>32. atopic eczema.mp.<BR/>33. exp NEURODERMATITIS/<BR/>34. neurodermatitis.mp.<BR/>35. infantile eczema.mp.<BR/>36. childhood eczema.mp.<BR/>37. Besniers' Prurigo.mp.<BR/>38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37<BR/>39. staphylococcus.mp. or exp STAPHYLOCOCCUS AUREUS/ or exp STAPHYLOCOCCUS/<BR/>40. staphylococcus.mp. or *STAPHYLOCOCCUS AUREUS/ or *STAPHYLOCOCCUS/<BR/>41. antibiotics.mp. or exp Anti-Bacterial Agents/<BR/>42. antiseptic$.mp. or exp Anti-Infective Agents, Local/<BR/>43. 39 or 40<BR/>44. (dermol$ or oilatum or emulsiderm or fusid$ or fucid$).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>45. (fucib$ or gregoderm or nystaform or quinocort).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>46. (terra-cortril or timodine or vioform or locoid or betnovate).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>47. (dermovate or trimovate or synalar or aureocort or triadcortyl).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>48. (bactroban or flucloxacillin or erythromycin or clindamycin).mp. [mp=title, original title, abstract, name of substance, mesh subject heading]<BR/>49. 41 or 42 or 44 or 45 or 46 or 47 or 48<BR/>50. 29 and 38 and 43 and 49</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-03-18 15:01:19 +0000" MODIFIED_BY="Diane A  Horsley" NO="3">
<TITLE MODIFIED="2008-03-18 15:00:55 +0000" MODIFIED_BY="Diane A  Horsley">EMBASE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-03-18 15:01:19 +0000" MODIFIED_BY="Diane A  Horsley">
<P>1. RANDOMIZED CONTROLLED TRIAL.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>2. CONTROLLED CLINICAL TRIAL.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>3. RANDOMIZED CONTROLLED TRIALS.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>4. RANDOM ALLOCATION.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>5. DOUBLE BLIND METHOD.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>6. SINGLE-BLIND METHOD.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>7. or/1-6<BR/>8. animal/ not human/<BR/>9. 7 not 8<BR/>10. CLINICAL TRIAL.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>11. exp CLINICAL TRIALS/<BR/>12. (clin$ adj25 trial$).ti,ab.<BR/>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14. PLACEBOS.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. RESEARCH DESIGN.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>18. or/10-17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. COMPARATIVE STUDY.sh.<BR/>22. exp EVALUATION STUDIES/<BR/>23. FOLLOW UP STUDIES.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>24. PROSPECTIVE STUDIES.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>25. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26. or/21-25<BR/>27. 26 not 8<BR/>28. 27 not (9 or 20)<BR/>29. 9 or 20 or 28<BR/>30. exp Dermatitis, Atopic/<BR/>31. atopic dermatitis.mp.<BR/>32. atopic eczema.mp.<BR/>33. exp NEURODERMATITIS/<BR/>34. neurodermatitis.mp.<BR/>35. infantile eczema.mp.<BR/>36. childhood eczema.mp.<BR/>37. Besniers' Prurigo.mp.<BR/>38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37<BR/>39. staphylococcus.mp. or exp STAPHYLOCOCCUS AUREUS/ or exp STAPHYLOCOCCUS/<BR/>40. staphylococcus.mp. or *STAPHYLOCOCCUS AUREUS/ or *STAPHYLOCOCCUS/<BR/>41. antibiotics.mp. or exp Anti-Bacterial Agents/<BR/>42. antiseptic$.mp. or exp Anti-Infective Agents, Local/<BR/>43. 39 or 40<BR/>44. (dermol$ or oilatum or emulsiderm or fusid$ or fucid$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>45. (fucib$ or gregoderm or nystaform or quinocort).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>46. (terra-cortril or timodine or vioform or locoid or betnovate).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>47. (dermovate or trimovate or synalar or aureocort or triadcortyl).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>48. (bactroban or flucloxacillin or erythromycin or clindamycin).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>49. 41 or 42 or 44 or 45 or 46 or 47 or 48<BR/>50. 29 and 38 and 43 and 49</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>